Document
false--12-31FY20192019-12-3100016236130.050.010.011200000000120000000066000000.1100.021750000000P25YP1Y260260220220P5YP3Y 0001623613 2019-01-01 2019-12-31 0001623613 2019-06-30 0001623613 2019-12-31 0001623613 2020-02-22 0001623613 2018-12-31 0001623613 us-gaap:CommonStockMember 2019-12-31 0001623613 us-gaap:TreasuryStockMember 2019-12-31 0001623613 us-gaap:TreasuryStockMember 2018-12-31 0001623613 us-gaap:CommonStockMember 2018-12-31 0001623613 2018-01-01 2018-12-31 0001623613 us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0001623613 2017-01-01 2017-12-31 0001623613 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001623613 us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0001623613 us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0001623613 us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0001623613 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001623613 us-gaap:CommonStockMember 2016-12-31 0001623613 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001623613 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001623613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001623613 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001623613 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001623613 us-gaap:NoncontrollingInterestMember 2017-12-31 0001623613 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001623613 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001623613 us-gaap:TreasuryStockMember 2017-12-31 0001623613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001623613 us-gaap:RetainedEarningsMember 2017-12-31 0001623613 us-gaap:CommonStockMember 2017-12-31 0001623613 us-gaap:NoncontrollingInterestMember 2019-12-31 0001623613 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001623613 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0001623613 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001623613 us-gaap:RetainedEarningsMember 2019-12-31 0001623613 us-gaap:NoncontrollingInterestMember 2016-12-31 0001623613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001623613 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001623613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001623613 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0001623613 2016-12-31 0001623613 us-gaap:NoncontrollingInterestMember 2018-12-31 0001623613 us-gaap:RetainedEarningsMember 2016-12-31 0001623613 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0001623613 2017-12-31 0001623613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001623613 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001623613 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001623613 us-gaap:TreasuryStockMember 2016-12-31 0001623613 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001623613 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001623613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001623613 us-gaap:NoncontrollingInterestMember 2017-01-01 2017-12-31 0001623613 us-gaap:RetainedEarningsMember 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember 2019-01-01 2019-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember 2017-01-01 2017-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:EuropeSegmentMember 2019-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:RestofWorldSegmentMember 2019-12-31 0001623613 2018-01-01 0001623613 us-gaap:AccountingStandardsUpdate201601Member 2017-12-31 0001623613 us-gaap:RetainedEarningsMember 2018-01-01 0001623613 us-gaap:AccountingStandardsUpdate201409Member 2017-12-31 0001623613 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0001623613 us-gaap:AccountingStandardsUpdate201712Member 2017-12-31 0001623613 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001623613 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-12-31 0001623613 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001623613 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001623613 myl:NoteSecuritizationFacilityMember 2019-12-31 0001623613 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2019-01-01 2019-12-31 0001623613 myl:ReceivablesFacilityMember 2019-12-31 0001623613 srt:MaximumMember 2019-01-01 2019-12-31 0001623613 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-01 2019-12-31 0001623613 srt:MinimumMember 2019-01-01 2019-12-31 0001623613 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2019-01-01 2019-12-31 0001623613 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-01-01 2019-12-31 0001623613 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0001623613 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0001623613 srt:MinimumMember myl:AccountingStandardsUpdate201820Member myl:InitialRightofuseAssetMember 2019-01-01 2019-01-01 0001623613 srt:MaximumMember myl:AccountingStandardsUpdate201820Member myl:InitialRightofuseAssetMember 2019-01-01 2019-01-01 0001623613 srt:MaximumMember myl:AccountingStandardsUpdate201820Member myl:LeaseLiabilityMember 2019-01-01 2019-01-01 0001623613 srt:MinimumMember myl:AccountingStandardsUpdate201820Member myl:LeaseLiabilityMember 2019-01-01 2019-01-01 0001623613 myl:AccountingStandardsUpdate201820Member us-gaap:RetainedEarningsMember 2019-01-01 0001623613 myl:VariableConsiderationReturnsMember myl:VariableConsiderationMember 2019-01-01 2019-12-31 0001623613 myl:RebatesPromotionalProgramsandOtherSalesAllowancesMember myl:VariableConsiderationMember 2019-01-01 2019-12-31 0001623613 myl:ChargebacksMember myl:VariableConsiderationMember 2019-12-31 0001623613 myl:RebatesPromotionalProgramsandOtherSalesAllowancesMember myl:VariableConsiderationMember 2019-12-31 0001623613 myl:GovernmentalRebateProgramsMember myl:VariableConsiderationMember 2019-01-01 2019-12-31 0001623613 myl:VariableConsiderationReturnsMember myl:VariableConsiderationMember 2019-12-31 0001623613 myl:VariableConsiderationMember 2019-01-01 2019-12-31 0001623613 myl:ChargebacksMember myl:VariableConsiderationMember 2019-01-01 2019-12-31 0001623613 myl:VariableConsiderationMember 2018-12-31 0001623613 myl:GovernmentalRebateProgramsMember myl:VariableConsiderationMember 2019-12-31 0001623613 myl:ChargebacksMember myl:VariableConsiderationMember 2018-12-31 0001623613 myl:GovernmentalRebateProgramsMember myl:VariableConsiderationMember 2018-12-31 0001623613 myl:VariableConsiderationReturnsMember myl:VariableConsiderationMember 2018-12-31 0001623613 myl:VariableConsiderationMember 2019-12-31 0001623613 myl:RebatesPromotionalProgramsandOtherSalesAllowancesMember myl:VariableConsiderationMember 2018-12-31 0001623613 myl:CardiovascularMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:OncologyMember 2017-01-01 2017-12-31 0001623613 myl:GastroenterologyMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:InfectiousDiseaseMember 2017-01-01 2017-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:CardiovascularMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:ImmunologyMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:DermatologyMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:ImmunologyMember 2017-01-01 2017-12-31 0001623613 myl:OncologyMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:InfectiousDiseaseMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:RespiratoryAllergyMember 2017-01-01 2017-12-31 0001623613 myl:RespiratoryAllergyMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:CardiovascularMember 2017-01-01 2017-12-31 0001623613 myl:CardiovascularMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:InfectiousDiseaseMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:OtherTherapeuticFranchisesMember 2017-01-01 2017-12-31 0001623613 myl:InfectiousDiseaseMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:WomensHealthcareMember 2017-01-01 2017-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:DiabetesMetabolismMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:DiabetesMetabolismMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember 2017-01-01 2017-12-31 0001623613 myl:WomensHealthcareMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:RespiratoryAllergyMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:GastroenterologyMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:DiabetesMetabolismMember 2017-01-01 2017-12-31 0001623613 myl:DermatologyMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:DermatologyMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:OncologyMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:GastroenterologyMember 2017-01-01 2017-12-31 0001623613 myl:DermatologyMember 2017-01-01 2017-12-31 0001623613 myl:GastroenterologyMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:RespiratoryAllergyMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:ImmunologyMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:WomensHealthcareMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:WomensHealthcareMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 myl:DiabetesMetabolismMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:OncologyMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:ImmunologyMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:WomensHealthcareMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:InfectiousDiseaseMember 2018-01-01 2018-12-31 0001623613 myl:DiabetesMetabolismMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:RespiratoryAllergyMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:InfectiousDiseaseMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:OncologyMember 2018-01-01 2018-12-31 0001623613 myl:OncologyMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:ImmunologyMember 2018-01-01 2018-12-31 0001623613 myl:DermatologyMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:InfectiousDiseaseMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:DermatologyMember 2018-01-01 2018-12-31 0001623613 myl:GastroenterologyMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember 2018-01-01 2018-12-31 0001623613 myl:ImmunologyMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:RespiratoryAllergyMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:RespiratoryAllergyMember 2018-01-01 2018-12-31 0001623613 myl:CardiovascularMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:DermatologyMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:DiabetesMetabolismMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:CardiovascularMember 2018-01-01 2018-12-31 0001623613 myl:CardiovascularMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:GastroenterologyMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:OtherTherapeuticFranchisesMember 2018-01-01 2018-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:DiabetesMetabolismMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:DermatologyMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:RespiratoryAllergyMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:OncologyMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:OncologyMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:DiabetesMetabolismMember 2018-01-01 2018-12-31 0001623613 myl:ImmunologyMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:ImmunologyMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:GastroenterologyMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:WomensHealthcareMember 2018-01-01 2018-12-31 0001623613 myl:InfectiousDiseaseMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:CardiovascularMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:WomensHealthcareMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:WomensHealthcareMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:GastroenterologyMember 2018-01-01 2018-12-31 0001623613 myl:InfectiousDiseaseMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:GastroenterologyMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:OncologyMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:OtherTherapeuticFranchisesMember 2019-01-01 2019-12-31 0001623613 myl:CardiovascularMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:RespiratoryAllergyMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:ImmunologyMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:DermatologyMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:RespiratoryAllergyMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:OncologyMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:OncologyMember 2019-01-01 2019-12-31 0001623613 myl:GastroenterologyMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:WomensHealthcareMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:InfectiousDiseaseMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:GastroenterologyMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:GastroenterologyMember 2019-01-01 2019-12-31 0001623613 myl:DermatologyMember 2019-01-01 2019-12-31 0001623613 myl:OtherTherapeuticFranchisesMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:RespiratoryAllergyMember 2019-01-01 2019-12-31 0001623613 myl:DiabetesMetabolismMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:DiabetesMetabolismMember 2019-01-01 2019-12-31 0001623613 myl:WomensHealthcareMember 2019-01-01 2019-12-31 0001623613 myl:DiabetesMetabolismMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:CardiovascularMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember 2019-01-01 2019-12-31 0001623613 myl:CardiovascularMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:DermatologyMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:InfectiousDiseaseMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:DermatologyMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:RespiratoryAllergyMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:WomensHealthcareMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:ImmunologyMember 2019-01-01 2019-12-31 0001623613 myl:DiabetesMetabolismMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:WomensHealthcareMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:CentralNervousSystemandAnesthesiaMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:CardiovascularMember 2019-01-01 2019-12-31 0001623613 myl:OncologyMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:InfectiousDiseaseMember 2019-01-01 2019-12-31 0001623613 us-gaap:OperatingSegmentsMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:ImmunologyMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:ImmunologyMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:SalesMember 2019-01-01 2019-12-31 0001623613 srt:MaximumMember myl:RevanceMember 2019-12-31 0001623613 myl:OtherCompaniesMember 2018-01-01 2018-12-31 0001623613 myl:TOBIMember 2019-01-01 2019-12-31 0001623613 myl:OtherCompaniesMember us-gaap:LicensingAgreementsMember 2018-01-01 2018-09-30 0001623613 myl:TOBIMember 2018-08-31 0001623613 myl:OtherCompaniesMember us-gaap:LicensingAgreementsMember 2018-10-01 2018-12-31 0001623613 myl:TOBIMember 2019-01-01 2019-03-31 0001623613 myl:TOBIMember 2019-05-28 0001623613 us-gaap:ProductMember myl:UpjohnInc.Member 2019-07-29 0001623613 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:ScenarioForecastMember 2020-03-31 2020-03-31 0001623613 myl:RevanceMember 2018-02-28 2018-02-28 0001623613 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2018-12-01 0001623613 myl:UpjohnInc.Member myl:PfizerInc.Member 2019-07-29 2019-07-29 0001623613 myl:RevanceMember 2019-08-22 2019-08-22 0001623613 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2019-01-01 2019-12-31 0001623613 myl:UpjohnInc.Member 2019-07-29 0001623613 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2019-03-31 2019-03-31 0001623613 myl:FKBMember 2019-02-27 2019-02-27 0001623613 myl:OtherCompaniesMember 2018-01-01 2018-09-30 0001623613 myl:OtherCompaniesMember 2019-01-01 2019-12-31 0001623613 myl:PfizerInc.Member 2019-07-29 0001623613 us-gaap:AllowanceForCreditLossMember 2019-12-31 0001623613 us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0001623613 us-gaap:AccountsReceivableMember 2019-12-31 0001623613 us-gaap:AllowanceForCreditLossMember 2018-12-31 0001623613 country:IN myl:VoluntaryRecallofValsartanandCertainCombinationsValsartanMedicinesMember 2019-01-01 2019-12-31 0001623613 country:IN myl:VoluntaryRecallofValsartanandCertainCombinationsValsartanMedicinesMember 2018-01-01 2018-12-31 0001623613 myl:CleanEnergyPartnershipsMember us-gaap:OtherAssetsMember 2019-12-31 0001623613 myl:CleanEnergyPartnershipsMember us-gaap:OtherAssetsMember 2018-12-31 0001623613 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-12-31 0001623613 us-gaap:NondesignatedMember 2019-01-01 2019-12-31 0001623613 us-gaap:FairValueHedgingMember 2019-01-01 2019-12-31 0001623613 us-gaap:LandAndLandImprovementsMember 2018-12-31 0001623613 us-gaap:ConstructionInProgressMember 2019-12-31 0001623613 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001623613 us-gaap:ConstructionInProgressMember 2018-12-31 0001623613 us-gaap:MachineryAndEquipmentMember 2018-12-31 0001623613 us-gaap:BuildingAndBuildingImprovementsMember 2019-12-31 0001623613 us-gaap:LandAndLandImprovementsMember 2019-12-31 0001623613 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001623613 us-gaap:OtherNoncurrentLiabilitiesMember 2019-12-31 0001623613 myl:CleanEnergyPartnershipsMember 2019-12-31 0001623613 myl:CleanEnergyPartnershipsMember 2018-12-31 0001623613 us-gaap:OtherNoncurrentLiabilitiesMember 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0001623613 srt:MaximumMember 2019-12-31 0001623613 srt:MinimumMember 2019-12-31 0001623613 2015-01-01 2015-12-31 0001623613 myl:CleanEnergyPartnershipsMember 2018-01-01 2018-12-31 0001623613 myl:EuropeSegmentMember 2018-04-01 0001623613 myl:NorthAmericaSpecialtyMember 2018-04-01 0001623613 myl:RespiratorydeliveryplatformMember 2017-06-30 0001623613 us-gaap:MeasurementInputControlPremiumMember 2018-06-30 0001623613 srt:MinimumMember us-gaap:MeasurementInputEbitdaMultipleMember 2018-06-30 0001623613 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember 2018-09-30 0001623613 us-gaap:OtherCurrentLiabilitiesMember myl:RespiratorydeliveryplatformMember 2019-01-01 2019-12-31 0001623613 srt:MinimumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2017-12-31 0001623613 srt:MinimumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001623613 myl:MeasurementInputEstimatedTaxRateMember 2019-12-31 0001623613 srt:MaximumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001623613 us-gaap:MeasurementInputDiscountRateMember myl:IncreasedDiscountRateDomain 2018-06-30 0001623613 srt:MinimumMember us-gaap:LicensingAgreementsMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001623613 srt:MinimumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0001623613 us-gaap:MeasurementInputLongTermRevenueGrowthRateMember myl:ReductioninTerminalValueGrowthRateDomain 2018-06-30 0001623613 myl:NorthAmericaGenericsMember 2018-04-01 0001623613 srt:MaximumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0001623613 2018-01-01 2018-06-30 0001623613 myl:RespiratorydeliveryplatformMember 2019-12-31 0001623613 us-gaap:GoodwillMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001623613 us-gaap:LicensingAgreementsMember 2019-01-01 2019-12-31 0001623613 myl:RespiratorydeliveryplatformMember 2019-01-01 2019-12-31 0001623613 srt:MaximumMember us-gaap:MeasurementInputEbitdaMultipleMember 2018-06-30 0001623613 srt:MaximumMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2017-12-31 0001623613 myl:RestofWorldSegmentMember 2018-04-01 0001623613 srt:MaximumMember us-gaap:LicensingAgreementsMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001623613 myl:RestofWorldSegmentMember 2019-12-31 0001623613 myl:RestofWorldSegmentMember 2018-12-31 0001623613 myl:EuropeSegmentMember 2019-12-31 0001623613 myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 myl:EuropeSegmentMember 2018-12-31 0001623613 myl:EuropeSegmentMember 2017-12-31 0001623613 myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 myl:NorthAmericaSegmentMember 2017-12-31 0001623613 myl:RestofWorldSegmentMember 2017-12-31 0001623613 myl:NorthAmericaSegmentMember 2019-12-31 0001623613 myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 myl:NorthAmericaSegmentMember 2018-12-31 0001623613 myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 myl:CardiovascularMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:DiabetesandMetabolismMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:DermatologicalMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:RespiratoryandAllergyMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:WomensHealthcareMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:CardiovascularMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:OncologyMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:RespiratoryandAllergyMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:InfectiousDiseaseMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:OncologyMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:OtherProductsMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:DiabetesandMetabolismMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:ImmunologicalAgentsMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:OtherProductsMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:CentralNervousSystemMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:WomensHealthcareMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:ImmunologicalAgentsMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:GastrointestinalMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:InfectiousDiseaseMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:DermatologicalMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 myl:GastrointestinalMember us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 myl:CentralNervousSystemMember us-gaap:LicensingAgreementsMember 2018-12-31 0001623613 us-gaap:LicensingAgreementsMember 2019-12-31 0001623613 us-gaap:InProcessResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:LicensingAgreementsMember 2017-01-01 2017-12-31 0001623613 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:LicensingAgreementsMember 2018-01-01 2018-12-31 0001623613 us-gaap:InProcessResearchAndDevelopmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0001623613 us-gaap:NondesignatedMember 2018-12-31 0001623613 us-gaap:NondesignatedMember 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 us-gaap:FairValueHedgingMember 2018-01-01 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2017-01-01 2017-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001623613 us-gaap:FairValueHedgingMember 2017-01-01 2017-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-01-01 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2017-01-01 2017-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2017-01-01 2017-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001623613 us-gaap:CashFlowHedgingMember 2015-01-01 2015-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2015-01-01 2015-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:OtherExpenseMember 2018-01-01 2018-12-31 0001623613 us-gaap:MortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:ExchangeTradedFundsMember 2019-12-31 0001623613 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember 2019-12-31 0001623613 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:OtherDebtSecuritiesMember 2019-12-31 0001623613 myl:ContingentConsiderationMember 2019-12-31 0001623613 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 us-gaap:InterestRateSwapMember 2019-12-31 0001623613 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2019-12-31 0001623613 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:CommonStockMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001623613 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001623613 us-gaap:MoneyMarketFundsMember 2019-12-31 0001623613 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:CommonStockMember 2019-12-31 0001623613 us-gaap:FairValueInputsLevel3Member myl:ContingentConsiderationMember 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember 2019-12-31 0001623613 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:MortgageBackedSecuritiesMember 2019-12-31 0001623613 us-gaap:CorporateBondSecuritiesMember 2019-12-31 0001623613 us-gaap:ExchangeTradedFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 us-gaap:DebtSecuritiesMember 2019-12-31 0001623613 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2017-01-01 2017-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001623613 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:DebtSecuritiesMember 2018-12-31 0001623613 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:FairValueInputsLevel3Member myl:ContingentConsiderationMember 2018-12-31 0001623613 us-gaap:ExchangeTradedFundsMember 2018-12-31 0001623613 myl:ContingentConsiderationMember 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:EquitySecuritiesMember 2018-12-31 0001623613 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 us-gaap:MortgageBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001623613 us-gaap:CommonStockMember 2018-12-31 0001623613 us-gaap:OtherDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember 2018-12-31 0001623613 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001623613 us-gaap:MortgageBackedSecuritiesMember 2018-12-31 0001623613 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:MoneyMarketFundsMember 2018-12-31 0001623613 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 us-gaap:OtherDebtSecuritiesMember 2018-12-31 0001623613 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember 2018-12-31 0001623613 us-gaap:ExchangeTradedFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 us-gaap:InterestRateSwapMember 2018-12-31 0001623613 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001623613 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2018-12-31 0001623613 us-gaap:EquitySecuritiesMember 2018-12-31 0001623613 us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001623613 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001623613 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001623613 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001623613 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001623613 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001623613 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:JaiPharmaLimitedMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember myl:AgilaSpecialtiesPrivateLimitedMember 2018-01-01 2018-12-31 0001623613 srt:MinimumMember myl:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001623613 srt:MaximumMember myl:ContingentConsiderationMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember myl:JaiPharmaLimitedMember 2018-01-01 2018-12-31 0001623613 myl:RespiratorydeliveryplatformMember 2018-01-01 2018-12-31 0001623613 us-gaap:DebtSecuritiesMember 2019-12-31 0001623613 us-gaap:DebtSecuritiesMember 2018-12-31 0001623613 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0001623613 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0001623613 myl:A2020EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0001623613 myl:A2025EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0001623613 myl:A2024EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0001623613 myl:A2028SeniorNotesMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0001623613 myl:A2020FloatingRateEuroNotesDomain us-gaap:NetInvestmentHedgingMember 2019-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2019-12-31 0001623613 myl:A2028SeniorNotesMember us-gaap:NetInvestmentHedgingMember 2018-12-31 0001623613 myl:A2020FloatingRateEuroNotesDomain us-gaap:NetInvestmentHedgingMember 2018-12-31 0001623613 myl:A2020EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2018-12-31 0001623613 myl:A2024EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2018-12-31 0001623613 myl:A2025EuroSeniorNotesMember us-gaap:NetInvestmentHedgingMember 2018-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:OtherExpenseMember 2017-01-01 2017-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:OtherExpenseMember 2018-01-01 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:OtherExpenseMember 2019-01-01 2019-12-31 0001623613 us-gaap:OtherNoncurrentLiabilitiesMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherNoncurrentLiabilitiesMember 2019-01-01 2019-12-31 0001623613 us-gaap:OtherNoncurrentLiabilitiesMember 2017-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember 2017-12-31 0001623613 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0001623613 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2018-12-31 0001623613 myl:A2048SeniorNotesMember us-gaap:SeniorNotesMember 2018-04-09 0001623613 myl:SeniorNotesTwoThousandNineteen2.50PrecentMember us-gaap:SeniorNotesMember 2018-06-15 0001623613 myl:NoteSecuritizationFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0001623613 myl:A2048SeniorNotesMember us-gaap:SeniorNotesMember 2019-01-01 2019-12-31 0001623613 us-gaap:SeniorNotesMember 2019-12-31 0001623613 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-07-27 0001623613 myl:SeniorNotesTwoThousandNineteen2.50PrecentMember us-gaap:SeniorNotesMember 2018-06-15 2018-06-15 0001623613 myl:CommercialPaperProgramMember 2017-06-06 2017-06-06 0001623613 myl:CommercialPaperProgramMember 2017-06-06 0001623613 myl:ReceivablesFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-12-31 0001623613 myl:ThreeFullFiscalQuartersFollowingQualifyingAcquisitionMember myl:A2018SeniorRevolvingCreditFacilityMember 2019-01-01 2019-12-31 0001623613 myl:SeniorNotesTwoThousandNineteenMember us-gaap:SeniorNotesMember 2018-06-15 2018-06-15 0001623613 myl:A2016TermLoansMember 2019-01-01 2019-12-31 0001623613 myl:SeniorNotesTwoThousandNineteenMember us-gaap:SeniorNotesMember 2018-04-28 2018-04-28 0001623613 myl:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-04-09 0001623613 myl:A2016SeniorRevolvingCreditFacilityMember 2016-11-22 0001623613 myl:A2020FloatingRateEuroNotesDomain us-gaap:SeniorNotesMember myl:EURIBORMember 2019-01-01 2019-12-31 0001623613 myl:SeniorNotesTwoThousandNineteenMember us-gaap:SeniorNotesMember 2013-11-13 0001623613 myl:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2019-01-01 2019-12-31 0001623613 myl:SeniorNotesTwoThousandNineteenMember us-gaap:SeniorNotesMember 2018-04-28 0001623613 myl:SeniorNotesTwoThousandEighteen3.0PercentMember us-gaap:SeniorNotesMember 2018-04-28 2018-04-28 0001623613 myl:A2025EuroSeniorNotesMember us-gaap:SeniorNotesMember 2018-05-23 0001623613 myl:SeniorNotesTwoThousandNineteen2.50PrecentMember 2019-12-31 0001623613 myl:TrailingFourQuartersMember myl:A2016SeniorRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-01-01 2019-12-31 0001623613 us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandEighteen3.0PercentMember 2015-12-09 0001623613 myl:A2025EuroSeniorNotesMember us-gaap:SeniorNotesMember 2019-01-01 2019-12-31 0001623613 myl:SeniorNotesTwoThousandEighteen2.6PercentMember us-gaap:SeniorNotesMember 2018-04-28 2018-04-28 0001623613 myl:SeniorNotesTwoThousandEighteen2.6PercentMember 2013-06-18 0001623613 myl:April2018SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:A2025EuroSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandNineteenMember 2018-12-31 0001623613 myl:A2024EuroSeniorNotesMember us-gaap:SeniorNotesMember 2016-11-22 0001623613 myl:OtherCurrentPortionofLongtermDebtMember 2018-12-31 0001623613 myl:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:A2020EuroSeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandFortySix5.25PrecentMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:A2028EuroSeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyOne3.15PrecentMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwenty3.75PercentMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandFortyThreeMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwenty3.75PercentMember 2019-12-31 0001623613 myl:OtherCurrentPortionofLongtermDebtMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:SeniorNotesMember 2013-12-24 0001623613 myl:A2020EuroSeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyOne3.15PrecentMember us-gaap:SeniorNotesMember 2016-06-09 0001623613 myl:A2020FloatingRateEuroNotesDomain us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:A2025EuroSeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:CurrentPortionofLongTermDebtMember 2019-12-31 0001623613 myl:A2016TermLoansMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyOne3.15PrecentMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree3.125PercentMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:A2016TermLoansMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandFortySix5.25PrecentMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:A2048SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree4.2PercentMember us-gaap:SeniorNotesMember 2013-11-13 0001623613 myl:A2020EuroSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwenty3.75PercentMember us-gaap:SeniorNotesMember 2015-12-09 0001623613 myl:SeniorNotesTwoThousandTwenty3.75PercentMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwentySix3.95PrecentMember us-gaap:SeniorNotesMember 2016-06-09 0001623613 myl:A2020EuroSeniorNotesMember 2018-12-31 0001623613 myl:A2020FloatingRateEuroNotesDomain us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwenty3.75PercentMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandTwentySix3.95PrecentMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:CurrentPortionofLongTermDebtMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree4.2PercentMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:SeniorNotesTwoThousandFortyThreeMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandFortyThreeMember us-gaap:SeniorNotesMember 2016-06-09 0001623613 myl:A2024EuroSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwentySix3.95PrecentMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:SeniorNotesTwoThousandFortySix5.25PrecentMember us-gaap:SeniorNotesMember 2016-06-09 0001623613 myl:A2048SeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:A2020FloatingRateEuroNotesDomain 2018-12-31 0001623613 myl:SeniorNotesTwoThousandTwentyThree4.2PercentMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:A2024EuroSeniorNotesMember us-gaap:SeniorNotesMember 2019-12-31 0001623613 myl:A2020FloatingRateEuroNotesDomain 2019-12-31 0001623613 myl:OtherLongTermDebtMember 2018-12-31 0001623613 myl:A2028EuroSeniorNotesMember us-gaap:SeniorNotesMember 2018-12-31 0001623613 myl:A2028EuroSeniorNotesMember us-gaap:SeniorNotesMember 2016-11-22 0001623613 myl:OtherLongTermDebtMember 2019-12-31 0001623613 myl:A2020EuroSeniorNotesMember us-gaap:SeniorNotesMember 2016-11-22 0001623613 myl:SeniorNotesTwoThousandNineteenMember 2019-12-31 0001623613 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001623613 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001623613 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2017-12-31 0001623613 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2016-12-31 0001623613 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0001623613 us-gaap:AccumulatedTranslationAdjustmentMember 2016-12-31 0001623613 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0001623613 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-01-01 2017-12-31 0001623613 us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001623613 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-12-31 0001623613 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-01-01 2017-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001623613 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001623613 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2019-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001623613 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:NetInvestmentHedgingMember 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-12-31 0001623613 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001623613 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001623613 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001623613 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001623613 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001623613 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001623613 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001623613 us-gaap:CashFlowHedgingMember us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-12-31 0001623613 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001623613 myl:NonU.S.statetaxauthorityMember 2018-01-01 2018-12-31 0001623613 myl:U.S.StateTaxAuthorityMember 2018-01-01 2018-12-31 0001623613 myl:NonU.S.statetaxauthorityMember 2017-01-01 2017-12-31 0001623613 myl:U.S.StateTaxAuthorityMember 2017-01-01 2017-12-31 0001623613 myl:OtherMember 2017-01-01 2017-12-31 0001623613 myl:NonU.S.statetaxauthorityMember 2019-01-01 2019-12-31 0001623613 myl:U.S.StateTaxAuthorityMember 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignCountryMember 2017-01-01 2017-12-31 0001623613 myl:LongTermIncentivePlan2003Member 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignCountryMember 2019-01-01 2019-12-31 0001623613 us-gaap:ForeignCountryMember 2018-01-01 2018-12-31 0001623613 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0001623613 myl:OtherMember 2019-01-01 2019-12-31 0001623613 us-gaap:DomesticCountryMember 2017-01-01 2017-12-31 0001623613 us-gaap:DomesticCountryMember 2018-01-01 2018-12-31 0001623613 myl:OtherMember 2018-01-01 2018-12-31 0001623613 myl:OtherforeignMember 2017-01-01 2017-12-31 0001623613 country:FR 2018-01-01 2018-12-31 0001623613 us-gaap:NonUsMember 2017-01-01 2017-12-31 0001623613 us-gaap:NonUsMember 2018-01-01 2018-12-31 0001623613 country:LU 2019-01-01 2019-12-31 0001623613 country:FR 2019-01-01 2019-12-31 0001623613 country:US 2017-01-01 2017-12-31 0001623613 country:US 2018-01-01 2018-12-31 0001623613 us-gaap:NonUsMember 2019-01-01 2019-12-31 0001623613 country:LU 2017-01-01 2017-12-31 0001623613 country:IE 2019-01-01 2019-12-31 0001623613 country:US 2019-01-01 2019-12-31 0001623613 country:LU 2018-01-01 2018-12-31 0001623613 myl:OtherforeignMember 2019-01-01 2019-12-31 0001623613 country:IE 2017-01-01 2017-12-31 0001623613 country:FR 2017-01-01 2017-12-31 0001623613 country:GI 2019-01-01 2019-12-31 0001623613 country:GI 2017-01-01 2017-12-31 0001623613 country:GI 2018-01-01 2018-12-31 0001623613 country:IE 2018-01-01 2018-12-31 0001623613 myl:OtherforeignMember 2018-01-01 2018-12-31 0001623613 2014-12-31 0001623613 myl:U.S.FederalTaxAuthorityMember 2019-12-31 0001623613 us-gaap:ForeignCountryMember myl:IndefiniteMember 2019-12-31 0001623613 us-gaap:ForeignCountryMember 2019-12-31 0001623613 us-gaap:ForeignCountryMember myl:FutureyearsMember 2019-12-31 0001623613 myl:U.S.StateTaxAuthorityMember 2019-12-31 0001623613 us-gaap:ScenarioForecastMember 2025-01-01 2025-12-31 0001623613 us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2017-01-01 2017-12-31 0001623613 us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2019-01-01 2019-12-31 0001623613 us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2018-01-01 2018-12-31 0001623613 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001623613 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001623613 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001623613 myl:OneTimeSpecialPerformanceBasedFiveYearRealizableValueIncentiveProgramDomain 2019-12-31 0001623613 myl:NotSubjecttoMarketConditionsMember myl:VestinthreeyearsorlessMember us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0001623613 2018-09-30 0001623613 myl:VestratablyinfiveyearsorlessMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001623613 srt:MaximumMember us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2019-01-01 2019-12-31 0001623613 myl:LongTermIncentivePlan2003Member 2018-01-01 2018-12-31 0001623613 myl:VestinthreeyearsorlessMember us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0001623613 myl:LongTermIncentivePlan2003Member 2019-12-31 0001623613 us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2017-12-31 0001623613 us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2019-12-31 0001623613 us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2018-12-31 0001623613 srt:MinimumMember us-gaap:EmployeeStockOptionMember myl:LongTermIncentivePlan2003Member 2019-01-01 2019-12-31 0001623613 myl:A2014ProgramMember myl:StockappreciationrightsandperformancesharesMember 2019-01-01 2019-12-31 0001623613 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-12-31 0001623613 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-12-31 0001623613 us-gaap:PensionPlansDefinedBenefitMember 2019-12-31 0001623613 us-gaap:PensionPlansDefinedBenefitMember 2018-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember 2019-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember 2019-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001623613 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0001623613 us-gaap:EquitySecuritiesMember 2019-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember 2018-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember 2018-12-31 0001623613 myl:AssetsheldbyinsurancecompaniesandotherMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 us-gaap:EquitySecuritiesMember 2018-12-31 0001623613 us-gaap:FixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember 2018-12-31 0001623613 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001623613 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0001623613 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001623613 us-gaap:PensionPlansDefinedBenefitMember 2017-01-01 2017-12-31 0001623613 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-12-31 0001623613 us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember 2019-01-01 2019-12-31 0001623613 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherPensionPlansPostretirementOrSupplementalPlansDefinedBenefitMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-12-31 0001623613 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-12-31 0001623613 us-gaap:PensionPlansDefinedBenefitMember 2017-12-31 0001623613 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2017-01-01 2017-12-31 0001623613 us-gaap:PensionPlansDefinedBenefitMember 2015-01-01 2015-12-31 0001623613 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2015-01-01 2015-12-31 0001623613 myl:FiscalYear2017Member 2019-12-31 0001623613 us-gaap:DeferredBonusMember 2019-01-01 2019-12-31 0001623613 myl:DeferredBaseSalaryMember 2019-01-01 2019-12-31 0001623613 myl:CardinalHealthIncMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001623613 myl:CardinalHealthIncMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001623613 myl:MckessonCorporationMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-12-31 0001623613 myl:AmeriSourceBergenCorporationMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-12-31 0001623613 myl:CardinalHealthIncMember us-gaap:SalesRevenueNetMember 2017-01-01 2017-12-31 0001623613 myl:AmeriSourceBergenCorporationMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001623613 myl:MckessonCorporationMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001623613 myl:MckessonCorporationMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001623613 myl:AmeriSourceBergenCorporationMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-12-31 0001623613 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:NorthAmericaSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember myl:RestofWorldSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:EuropeSegmentMember 2019-01-01 2019-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductAndServiceOtherMember myl:NorthAmericaSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductAndServiceOtherMember myl:EuropeSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductAndServiceOtherMember myl:RestofWorldSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-12-31 0001623613 country:NL 2019-01-01 2019-12-31 0001623613 country:NL 2018-01-01 2018-12-31 0001623613 country:IN 2019-01-01 2019-12-31 0001623613 country:NL 2017-01-01 2017-12-31 0001623613 country:IN 2017-01-01 2017-12-31 0001623613 country:IN 2018-01-01 2018-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductAndServiceOtherMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0001623613 myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductAndServiceOtherMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductAndServiceOtherMember myl:NorthAmericaSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:IntersegmentEliminationMember 2017-01-01 2017-12-31 0001623613 myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:RestofWorldSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0001623613 us-gaap:IntersegmentEliminationMember myl:EuropeSegmentMember 2017-01-01 2017-12-31 0001623613 srt:NonGuarantorSubsidiariesMember 2017-01-01 2017-12-31 0001623613 srt:GuarantorSubsidiariesMember 2017-01-01 2017-12-31 0001623613 srt:SubsidiaryIssuerMember 2017-01-01 2017-12-31 0001623613 srt:ConsolidationEliminationsMember 2017-01-01 2017-12-31 0001623613 srt:ParentCompanyMember 2017-01-01 2017-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0001623613 srt:ParentCompanyMember us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:ProductAndServiceOtherMember 2017-01-01 2017-12-31 0001623613 srt:GuarantorSubsidiariesMember 2018-12-31 0001623613 srt:SubsidiaryIssuerMember 2018-12-31 0001623613 srt:NonGuarantorSubsidiariesMember 2018-12-31 0001623613 srt:ParentCompanyMember 2018-12-31 0001623613 srt:ConsolidationEliminationsMember 2018-12-31 0001623613 srt:ConsolidationEliminationsMember 2018-01-01 2018-12-31 0001623613 srt:GuarantorSubsidiariesMember 2018-01-01 2018-12-31 0001623613 srt:ParentCompanyMember 2018-01-01 2018-12-31 0001623613 srt:NonGuarantorSubsidiariesMember 2018-01-01 2018-12-31 0001623613 srt:SubsidiaryIssuerMember 2018-01-01 2018-12-31 0001623613 srt:NonGuarantorSubsidiariesMember 2017-12-31 0001623613 srt:ConsolidationEliminationsMember 2017-12-31 0001623613 srt:ParentCompanyMember 2017-12-31 0001623613 srt:SubsidiaryIssuerMember 2017-12-31 0001623613 srt:GuarantorSubsidiariesMember 2017-12-31 0001623613 srt:SubsidiaryIssuerMember 2016-12-31 0001623613 srt:ConsolidationEliminationsMember 2016-12-31 0001623613 srt:ParentCompanyMember 2016-12-31 0001623613 srt:NonGuarantorSubsidiariesMember 2016-12-31 0001623613 srt:GuarantorSubsidiariesMember 2016-12-31 0001623613 srt:ConsolidationEliminationsMember 2019-01-01 2019-12-31 0001623613 srt:ParentCompanyMember 2019-01-01 2019-12-31 0001623613 srt:SubsidiaryIssuerMember 2019-01-01 2019-12-31 0001623613 srt:GuarantorSubsidiariesMember 2019-01-01 2019-12-31 0001623613 srt:NonGuarantorSubsidiariesMember 2019-01-01 2019-12-31 0001623613 srt:NonGuarantorSubsidiariesMember 2019-12-31 0001623613 srt:ConsolidationEliminationsMember 2019-12-31 0001623613 srt:SubsidiaryIssuerMember 2019-12-31 0001623613 srt:GuarantorSubsidiariesMember 2019-12-31 0001623613 srt:ParentCompanyMember 2019-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0001623613 srt:ParentCompanyMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 srt:ParentCompanyMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:NetInvestmentHedgingMember 2018-01-01 2018-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0001623613 srt:ParentCompanyMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 srt:ParentCompanyMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:CashFlowHedgingMember 2017-01-01 2017-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:NetInvestmentHedgingMember 2017-01-01 2017-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0001623613 srt:ParentCompanyMember us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:ProductAndServiceOtherMember 2018-01-01 2018-12-31 0001623613 srt:ParentCompanyMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0001623613 srt:ParentCompanyMember us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-12-31 0001623613 srt:SubsidiaryIssuerMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001623613 srt:ConsolidationEliminationsMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001623613 srt:NonGuarantorSubsidiariesMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001623613 srt:GuarantorSubsidiariesMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001623613 srt:ParentCompanyMember us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001623613 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherRestructuringMember 2018-01-01 2018-12-31 0001623613 us-gaap:OtherRestructuringMember 2017-12-31 0001623613 us-gaap:OtherRestructuringMember 2019-01-01 2019-12-31 0001623613 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-12-31 0001623613 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-12-31 0001623613 us-gaap:OtherRestructuringMember 2018-12-31 0001623613 us-gaap:EmployeeSeveranceMember 2018-12-31 0001623613 us-gaap:EmployeeSeveranceMember 2019-12-31 0001623613 us-gaap:EmployeeSeveranceMember 2017-12-31 0001623613 us-gaap:OtherRestructuringMember 2019-12-31 0001623613 srt:MaximumMember myl:TheravanceBiopharmaMember 2015-01-30 2015-01-30 0001623613 myl:FKBMember 2018-09-20 2018-09-20 0001623613 myl:MomentaMember 2016-01-08 0001623613 myl:TheravanceBiopharmaMember 2019-01-01 2019-12-31 0001623613 myl:FiscalYear2017Member srt:MaximumMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-12-31 0001623613 myl:MomentaMember 2018-01-01 2018-12-31 0001623613 myl:MomentaMember 2019-01-01 2019-12-31 0001623613 myl:MomentaMember 2016-01-08 2016-01-08 0001623613 myl:OtherCompaniesMember us-gaap:LicensingAgreementsMember 2019-01-01 2019-12-31 0001623613 myl:MomentaMember 2017-01-01 2017-12-31 0001623613 myl:GenericBiologicCompoundsCollaborationMember 2013-02-11 2013-02-12 0001623613 myl:SECDivisionofEnforcementEpiPenclassificationsettlementMember 2019-07-01 2019-09-30 0001623613 myl:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember 2016-02-12 2016-02-12 0001623613 myl:EpiPenIsraeliSecuritiesLitigationMember 2016-10-13 2016-10-13 0001623613 myl:ModafinilAntitrustLitigationAndFtcInquiryMember myl:OtherCompaniesMember 2015-07-10 2015-07-10 0001623613 srt:ParentCompanyMember myl:EUCommissionProceedingsPerindorprilMember myl:AntitrustProceedingsMember 2014-07-08 2014-07-09 0001623613 myl:ModafinilAntitrustLitigationAndFtcInquiryMember 2019-12-31 0001623613 myl:MultiDistrictLitigationMember 2019-12-31 0001623613 myl:OtherMember 2017-06-30 0001623613 myl:ProductLiabilityMember 2018-12-31 0001623613 myl:ModafinilAntitrustLitigationAndFtcInquiryMember 2019-01-01 2019-12-31 0001623613 myl:ModafinilAntitrustLitigationAndFtcInquiryMember myl:OtherCompaniesMember 2006-04-26 2006-04-27 0001623613 myl:AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember 2019-12-31 0001623613 srt:SubsidiariesMember myl:EUCommissionProceedingsPerindorprilMember myl:AntitrustProceedingsMember 2014-07-08 2014-07-09 0001623613 myl:EUCommissionProceedingsCitalopramMember 2019-12-31 0001623613 myl:EpiPenAutoInjectorCivilLitigationMember 2019-12-31 0001623613 srt:ParentCompanyMember myl:EUCommissionProceedingsPerindorprilMember myl:AntitrustProceedingsMember 2014-10-01 2014-12-31 0001623613 us-gaap:OtherCurrentLiabilitiesMember 2017-06-30 0001623613 myl:CelgeneMember 2019-01-01 2019-12-31 0001623613 myl:ModafinilAntitrustLitigationAndFtcInquiryMember myl:OtherCompaniesMember 2016-07-28 2016-07-28 0001623613 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0001623613 myl:EUCommissionProceedingsCitalopramMember 2013-06-01 2013-06-19 0001623613 srt:ParentCompanyMember myl:U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember 2016-02-12 2016-02-12 0001623613 myl:AnticompetitiveConductwithGenericDrugsMember 2019-12-31 0001623613 myl:SECDivisionofEnforcementEpiPenclassificationsettlementMember 2019-10-01 2019-10-31 0001623613 myl:AmendedAnticompetitiveConductwithGenericDrugsMember 2019-12-31 0001623613 myl:ProductLiabilityMember 2019-12-31 0001623613 us-gaap:AllowanceForCreditLossMember 2016-12-31 0001623613 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0001623613 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0001623613 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0001623613 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0001623613 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0001623613 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0001623613 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0001623613 us-gaap:AllowanceForCreditLossMember 2017-12-31 0001623613 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0001623613 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0001623613 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 xbrli:pure iso4217:USD xbrli:shares myl:country xbrli:shares myl:segments iso4217:USD iso4217:EUR xbrli:shares iso4217:GBP myl:increase iso4217:EUR myl:other_drug_manufacturers myl:drugs myl:Product


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K
Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the Fiscal Year Ended December 31, 2019
OR
Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the transition period from              to             .
Commission file number 333-199861
MYLAN N.V.
(Exact name of registrant as specified in its charter)
Netherlands
 
98-1493528
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, England
(Address of principal executive offices)
+44 (0) 1707-853-000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class:
 
Trading Symbol(s)
 
Name of Each Exchange on Which Registered:
Ordinary shares, nominal value €0.01
 
MYL
 
The NASDAQ Stock Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes        No  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes        No  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes        No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes        No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
  
Accelerated filer
 
Non-accelerated filer
 
  
Smaller reporting company
 
 
 
 
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes        No  
The aggregate market value of the outstanding ordinary shares, nominal value 0.01, of the registrant other than shares held by persons who may be deemed affiliates of the registrant, as of June 30, 2019, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $12,814,190,996.
The number of ordinary shares outstanding, nominal value 0.01, of the registrant as of February 24, 2020 was 516,177,189.
INCORPORATED BY REFERENCE
Document
Part of Form 10-K into Which
Document is Incorporated
An amendment to this Form 10-K will be filed no later than 120 days after the close of registrant’s fiscal year.
III
 




MYLAN N.V.
INDEX TO FORM 10-K
For the Year Ended December 31, 2019
 
 
 
Page
PART I
 
ITEM 1.
ITEM 1A.
ITEM 1B.
ITEM 2.
ITEM 3.
 
 
 
PART II
 
ITEM 5.
ITEM 6.
ITEM 7.
ITEM 7A.
ITEM 8.
ITEM 9.
ITEM 9A.
ITEM 9B.
 
 
 
PART III
 
ITEM 10.
ITEM 11.
ITEM 12.
ITEM 13.
ITEM 14.
 
 
 
PART IV
 
ITEM 15.

2



PART I
ITEM 1.
Business
Mylan N.V. (the successor registrant to Mylan Inc.), along with its subsidiaries (collectively, the “Company,” “Mylan,” “our” or “we”), is a global pharmaceutical company committed to setting new standards in healthcare and providing 7 billion people access to high quality medicine. We offer a portfolio of more than 7,500 products, including prescription generic, branded generic, brand-name drugs and over-the-counter (“OTC”) remedies. We market our products in more than 165 countries and territories. As of December 31, 2019, our global workforce totaled approximately 35,000 employees and external contractors. Some of our employees are unionized or part of works councils or trade unions.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-ourmissiona01.jpg
On July 29, 2019, the Company, Pfizer Inc. (“Pfizer”), Upjohn Inc., a wholly-owned subsidiary of Pfizer (“Upjohn” or “Newco”), and certain other affiliated entities entered into a Business Combination Agreement (the “Business Combination Agreement”) pursuant to which the Company will combine with Pfizer’s Upjohn Business (the “Upjohn Business”) in a Reverse Morris Trust transaction (the “Combination”). Newco, which will be the parent entity of the combined Upjohn Business and Mylan business, will be renamed “Viatris” effective as of the closing of the Combination. The Upjohn Business is a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent solid oral dose legacy brands, such as Lyrica, Lipitor, Celebrex and Viagra. The consummation of the Combination is subject to various customary closing conditions, including receipt of regulatory approvals and approval of the Combination by Mylan’s shareholders, and is expected to close in mid-2020. See Item 1A, “Risk Factors,” Item 7, “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and Note 4 Acquisitions and Other Transactions of the notes to consolidated financial statements included in Item 8 in this Annual Report on Form 10-K for additional information regarding the Combination.
Business Evolution
Mylan was founded in 1961 as a privately-owned company to help people in rural communities in the United States (“U.S.”) state of West Virginia obtain quality affordable medicines. Originally a distributor of other firms’ products, we grew over time into one of the nation’s largest manufacturers of generic drugs (“Gx”). Mylan became a publicly traded company in 1973.
Approximately a decade ago, in response to industry changes, Mylan developed and began executing on a strategy to set new standards in healthcare. Our goal was to create a durable business model that would harness the power of competition to drive innovations capable of increasing access to medicine.
Our strategy involved creating robust research, manufacturing, supply chain and commercial platforms on a global scale; substantially expanding our portfolio of medicines; diversifying by geography, product type and channel; maintaining our commitment to quality; cultivating our corporate culture and workforce; and continuing to manage for the long-term.
Acquisitions, including that of Matrix Laboratories Limited (2007); Merck KGaA’s generics and specialty pharmaceutical business (2007); the EPD Business (as defined below) (2015) and Meda AB (publ.) (“Meda”) (2016), have played a significant role in the evolution of the Company.

3



Mylan N.V. was originally incorporated as a private limited liability company in the Netherlands in 2014. Mylan became a public limited liability company in the Netherlands through its acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics (“Bx”) business (the “EPD Business”) on February 27, 2015. Mylan’s corporate seat is in the Netherlands; our principal executive offices are in England and our group’s global headquarters is in the U.S.
We expect that the planned combination with the Upjohn Business will not only complete this strategy, but will also further unlock the true value of our platform. We also expect to acquire complementary products and product-development capabilities in the future. As part of our acquisition and integration efforts, Mylan has been and is planning to continue to remain focused on how to best optimize and maximize all of our assets across the organization and all geographies.
Unless otherwise indicated, industry data included in this Item 1 is sourced from IQVIA Holdings Inc. and is for the twelve months ended November 2019. Mylan product information is from internal sources and is as of December 31, 2019.
Business Model and Operations
Our mission is grounded in our conviction that every person should have the opportunity to live the healthiest life possible. For this reason, providing access to medicine is an important goal of our business model, pictured below.
OUR BUSINESS MODEL
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-ourbusinessmodelupdatedv2.jpg
To provide access, we seek to satisfy the needs of an incredibly diverse global pharmaceutical marketplace whose economic and political systems, approaches to delivering and paying for healthcare, languages and traditions, and customer and patient requirements vary by location and over time.
It is with these considerations in mind that we built and scaled our commercial, operational and scientific platforms, which we believe meet the evolving needs of customers in ways that are globally consistent and locally sensitive. As a result, Mylan now reaches patients in nearly every corner of the world with a wide range of products.
We believe that the breadth and depth - i.e., the diversity - of our business and platforms have rendered our business durable, as we are not dependent on any single market or product.

4



We also believe that durability not only helps us expand people’s access to medicine, it also allows us to better compete on a global basis than many of our peers. Our primary competitors in the prescription drugs space include other pharmaceutical companies, including manufacturers of brand-name, generic drugs and branded drug companies, that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. Our OTC products face competition from pharmaceutical companies and from retailers that carry their own private-label brands.
DURABILITY COMPONENTS

https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-durabiltiymodelnew.jpg

We have structured our business and strive to operate it in ways that maximize our operational and financial results. Operationally, for instance, we have chosen to vertically integrate much of our manufacturing activity; this means producing many of our own active pharmaceutical ingredients (“APIs”) and finished dosage forms. This approach affords us greater control over the cost and quality of what we make. All of the facilities discussed below are included in our reportable segments (North America, Europe, and Rest of World) primarily based on the location of the facility.
Our principal administrative, research and development (“R&D”) and manufacturing facilities are located around the world; many of the latter are strategically located in proximity to key markets.
In the U.S. and Puerto Rico, we own 16 manufacturing, distribution, and administrative facilities. Principal facilities include the group’s global headquarters in Canonsburg, Pennsylvania; our campus in Morgantown, West Virginia, which includes an R&D center of excellence and manufacturing plant; and our distribution center in Greensboro, North Carolina.
Outside the U.S. and Puerto Rico, we own 37 production, distribution, and administrative facilities in 15 countries.

5



In Europe, principal facilities include our principal executive offices in Hatfield, Hertfordshire, England; our global center in Dublin, Ireland; as well as key facilities in Ireland, Hungary, and France.
We also operate key facilities in India, Australia, and Japan. In India, principal facilities include our global center in Bangalore; an R&D center of excellence in Hyderabad; and several manufacturing plants located throughout the country.
Mylan also leases manufacturing, warehousing, distribution and administrative facilities in various locations, both within and outside of the U.S. Finally, Mylan relies upon many of our collaboration partners’ manufacturing and other facilities throughout the world.
We believe all our facilities are in good operating condition, the machinery and equipment are well-maintained, the facilities are suitable for their intended purposes and they have capacities adequate for the current operations.
The APIs and other materials and supplies we use in our manufacturing operations are purchased from third parties, and some are produced internally. Occasionally, however, resources we need are available from only a single supplier. Like many pharmaceutical companies, we supplement our production footprint through arrangements with other manufacturers.
Facilities and records related to our products are subject to periodic inspection by the U.S. Food and Drug Administration (the “FDA”), the European Medicines Agency (“EMA”), the Therapeutic Goods Administration in Australia and other authorities, as applicable. In addition, authorities often conduct pre-approval plant inspections to determine whether our systems and processes comply with current Good Manufacturing Practices (“cGMP”) and other regulations, and clinical-trial reviews to evaluate regulatory compliance and data integrity. Our suppliers, contract manufacturers, clinical trial partners and other business partners are subject to similar regulations and periodic inspections.
Moreover, as a part of our commitment to caring for the environment, we strive to comply in all material respects with applicable environmental laws and regulations. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.
Customers and Marketing
Our customers are essential in helping us create better health for a better world by making our products available to patients. Numbering in the tens of thousands, our customers include retail pharmacies; wholesalers and distributors; payers, insurers and governments; and institutions such as hospitals; among others. See “Channel Types” below for more information about our customers.
The table below displays the percentage of consolidated net sales to our largest customers during the years ended December 31, 2019, 2018 and 2017.
 
Percentage of Consolidated Net Sales
 
2019
 
2018
 
2017
McKesson Corporation
15
%
 
12
%
 
13
%
AmerisourceBergen Corporation
9
%
 
8
%
 
8
%
Cardinal Health, Inc.
8
%
 
8
%
 
10
%
We serve our customers through a team of approximately 7,000 sales and marketing professionals, all of whom are focused on establishing Mylan as our customers’ partner of choice. To best meet customers’ needs, Mylan manages its business on a geographic basis.
In addition to being dynamic, the pharmaceutical industry is complex. How it functions, how it is regulated and how it provides patients access varies by location. Similarly, competition is affected by many factors. Examples of factors include innovation and development, timely approval of prescription drugs by health authorities, manufacturing capabilities, product quality, marketing effectiveness, portfolio size, customer service, consumer acceptance, product price, political stability and the availability of funding for healthcare.

6



Certain parts of our business also are affected by seasonality, e.g., due to the timing and severity of peak cough, cold and flu incidence, which can cause variability in sales trends for some of our products. While seasonality may affect quarterly comparisons within a fiscal year; it generally is not material to our annual consolidated results.
For these and other reasons, Mylan’s sales and marketing efforts vary accordingly by product, market and channel type, each of which is described below.
See the Application of Critical Accounting Policies section in Item 7 of this Annual Report on Form 10-K for more information related to customer arrangements.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-pharmaceuticalindustrycharac.jpg
Product Types
Mylan markets prescription brand-name drugs; unbranded and branded prescription generic drugs; OTC products and APIs.
Brand-name drugs (“Rx”) typically are prescription pharmaceuticals that are sufficiently novel as to be protected by patents or other forms of exclusivity. As such, these drugs, which bear trade names, may be produced and sold only by those owning the rights, subject to certain challenges that other companies may make. Developing new medicines can take years and significant investment. Only a few promising therapies ever enter clinical trials. Fewer still are approved for sale by health authorities, at which point marketing to healthcare providers and consumers begins.
Because patents and exclusivities last many years, they serve as an incentive to developers. During the periods protected, developers often recoup their investments and earn a profit. In many high-income countries, the brand business often is characterized by higher margins on lower volumes - especially as compared with generic manufacturers. We have acquired most of the branded products we offer.
Generic drugs (“Gx”) are therapeutically equivalent versions of brand-name medicines. Generics generally become available once the patents and other exclusivities on their branded counterparts expire. Gx products typically are sold under their International Nonproprietary Names (“INNs”). INNs facilitate the identification of pharmaceutical substances or APIs. Each INN is unique and globally recognized. A nonproprietary name also is known as a generic name.
Mylan, like many other generic drugmakers, invests significant sums in R&D and in manufacturing capacity. We also often incur substantial litigation expense as a result of challenging brand patents or exclusivities. But because generic

7



drugmakers are not required to reproduce expensive clinical trials and seldom engage in product promotion, Gx typically cost far less than branded drugs. The generics business is generally characterized by lower margins on higher volumes, as most generic drugmakers, Mylan included, offer a relatively large number of products.
Branded generics (“Bx”) are off-patent products that are sold under an approved proprietary name for marketing purposes. Rx products often become Bx products once patent protections or other forms of exclusivity expire. Bx products are common in many countries outside the U.S., including emerging markets. In addition, complex products, such as biosimilars (that is, a biological product that is highly similar to an already approved reference biological product, and for which there are no clinically meaningful differences between the biosimilar and the reference biological product in terms of safety, purity and potency), often are marketed under a brand-name.
Rx and Bx products are more sensitive to promotion than are unbranded generic products. They therefore represent the focus of most of our sales representatives and product-level marketing activity.
OTC products are sold directly to consumers, without a prescription and without reimbursement. As with prescription medicines, properly approved OTC products are proven to be safe and effective when used as directed. OTC products also are subject to various regulatory requirements, including those applicable to manufacturing, advertising and promotion. OTC products may be sold under a brand-name or a molecule name.
Our API is sold through a dedicated sales and marketing team primarily to pharmaceutical companies throughout the world.
Market Types
Like other drug companies, Mylan focuses its sales and marketing efforts on the people who make key decisions around pharmaceutical prescribing, dispensing or buying. Decision-makers vary by country or region, reflecting law and custom, giving rise to different types of pharmaceutical markets. Many countries feature a mix of or hybrids of various market types, though Mylan may focus on just one type.
In prescription markets, physicians decide which medicines patients will take. Pharmacies then dispense the products as directed. Drug companies employ sales forces to educate doctors about the clinical benefits of their products. Representatives call on individual doctors or group practices; the process is known as detailing. Examples of countries served by Mylan that are mainly prescription markets are Japan, China, Russia, Turkey, Poland and Mexico.
In substitution markets, pharmacists generally are authorized (and in some cases required) by law to dispense an unbranded or branded generic, if available, in place of a brand-name medicine, or vice versa. Drug companies may use sales forces in these markets too, with representatives calling on and educating pharmacy personnel about their organization and products. Examples of countries served by Mylan that are mainly substitution markets are France, Italy, Spain, Portugal and Australia.
In tender markets, payers, such as governments or insurance companies, negotiate the lowest price for a drug (or group of drugs) on behalf of their constituents or members. In exchange, the chosen supplier’s product is placed on the payer’s formulary, or list of covered prescriptions. Often, a supplier’s drug is the only one available in an entire class of drugs. Large sales forces are not needed to reach these decision-makers. Examples of generic markets served by Mylan that are mainly tender markets are Germany, New Zealand, Sweden and Denmark.
In distribution markets, retailers and wholesalers make drug-purchasing decisions. Large sales forces are not needed to reach the decision-makers representing these organizations. Note, however, that pharmacists operating in distribution markets also may be authorized to make substitution decisions when dispensing medicines. Examples of countries served by Mylan that are mainly distribution markets are the U.S., the United Kingdom (“U.K.”) and Norway.
The allocation of our sales and marketing resources reflects the characteristics of these different market types.
In the case of OTC products, consumers are the decision-makers. OTC products are commonly sold via retail channels, such as pharmacies, drugstores and supermarkets. This makes their sale and marketing comparable to other retail businesses, with broad advertising and trade-channel promotion. Consumers often are loyal to well-known OTC brands. For this reason, suppliers of OTC products, Mylan included, must invest the time and resources needed to build strong OTC brand names.

8



Channel Types
Mylan’s products make their way to patients through a variety of intermediaries, or channels.
Pharmaceutical wholesalers/distributors purchase prescription medicines and other medical products directly from manufacturers for storage in warehouses and distribution centers. The distributors then fill orders placed by healthcare providers and other authorized buyers.
Pharmaceutical retailers purchase products directly from manufacturers or wholesalers/distributors. They then sell them to consumers in relatively small quantities for personal use.
Institutional pharmacies address the unique needs of hospitals, nursing homes and other such venues. Among the services provided are specialized packaging, including for injectables and unit-dose products, for controlled administration.
Mail-order and e-commerce pharmacies receive prescriptions by mail, fax, phone or the internet at a central location; process them in large, mostly automated centers; and mail the drugs to the consumer.
Specialty pharmacies focus on managing the handling and service requirements associated with high-cost and more-complex drug therapies, such as those used to treat patients with rare or serious diseases.
Business Segments
Consistent with Mylan’s focus on bringing its broad and diversified portfolio products to people in markets everywhere, the company reports results in three segments on a geographic basis as follows: North America, Europe and Rest of World.
Our North America segment comprises our operations in the U.S. and Canada. Our Europe segment encompasses our operations across 35 countries, including France, Italy, Germany, the U.K. and Spain. Our Rest of World segment reflects our operations in more than 120 countries outside of our North America and Europe segments.
The charts below display Mylan’s net sales by segment and by product type for the year ended December 31, 2019. Net sales are generated primarily from the sale of pharmaceutical products, including API.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-chart-e05cdf2f2b415ab09eb.jpg https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-chart-7f286066e9205518b1a.jpg
With respect to product type, generic offerings continue to represent over 50% of our net sales, in keeping with Mylan’s emphasis on expanding people’s access to medicine.

9



In addition, we have focused our products in 10 major therapeutic areas. We have critical mass in these areas, though our sales emphasis varies by market according to need and opportunity.
MYLAN’S MAJOR THERAPEUTIC AREAS*
 
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea01.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea02.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea03.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea04.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea05.jpg
Products
Cardiovascular
CNS & Anesthesia
Dermatology
Diabetes & Metabolism
Gastroenterology
Current
1,150
1,900
500
450
700
Pipeline
300
400
60
250
100
 
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea06.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea07.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea08.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea09.jpg
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-capturea10.jpg
Products
Immunology
Infectious Disease
Oncology
Respiratory & Allergy
Women’s Health
Current
80
1,100
450
600
650
Pipeline
75
800
500
150
150
 
 
 
 
 
 
*Product defined by product/dosage form/country. Products taken from internal data and rounded.
North America
Mylan’s business in North America is driven mainly by our operations in the U.S., where we are one of the largest providers of prescription medicines. The U.S. pharmaceutical industry is very competitive, and the primary means of competition are innovation and development, timely FDA approval, manufacturing capabilities, product quality, marketing, portfolio size, customer service, reputation and price. We rely on cost-effective manufacturing processes to meet the rapidly changing needs of our customers around a reliable, high quality supply of generic pharmaceutical products.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-chart-94c397e3dbd7574fa32.jpg
Gx are widely accepted in the U.S., accounting in 2019 for approximately 90% of prescriptions dispensed, but only about 20% of total prescription drug costs. Over the last five years, Mylan has launched more generics in the U.S. than any other company.
Among our branded prescription products are EpiPen® Auto-Injector, Perforomist® Inhalation Solution and Dymista®. YUPELRITM, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease, was launched in December 2018. Our OTC portfolio includes Cold-EEZE®, MidNite® and Vivarin®, as well as other products. Our promotion efforts are supported by a salesforce of approximately 300 sales representatives.

10



New product launches are an important growth driver. Important recent launches include complex products such as Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab), and Wixela™ Inhub™ (AB rated generic of Advair Diskus®). Our emphasis on complex products, some of which we develop in collaboration with other companies, is evidenced by our efforts to develop and introduce generic versions of Symbicort®, Restasis®, and a biosimilar to Avastin® in North America.
While our U.S. customer base is extensive, it increasingly comprises a small number of very large firms as the pharmaceutical industry continues to undergo tremendous change and consolidation. Mylan is well positioned to serve such customers - in the U.S. and elsewhere - due to the scale we have built in terms of R&D, API and finished-dosage-form manufacturing, and portfolio breadth.
Europe
Mylan’s business in Europe is driven by our scale across 35 countries.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-chart-b2c83c35a1275ed0b79.jpg
Generic medicines have transformed healthcare in the region over the last decade by significantly increasing patients’ access to medicine in an era of rising demand for healthcare services and constrained finances. In 2019 generic pharmaceuticals represented more than half of medicines used in Europe, but less than one quarter of total drug costs. Europe represents the world’s second largest generic pharmaceuticals market, by value. The European markets, where many governments provide healthcare at a low direct cost to consumers and regulate pharmaceutical prices or patient reimbursement levels, continue to be highly competitive, especially in terms of pricing, quality standards, service levels and product portfolio. Our leadership position in a number of countries provides us a platform to fulfill the needs of patients, physicians, pharmacies, customers and payors.
Among our many branded prescription products are Creon®, Influvac® and Dymista®. Our OTC portfolio includes Brufen®, CB12® and EndWarts®, as well as other products. Our promotional efforts in the region are supported by approximately 2,500 sales representatives.
New product launches are an important growth driver. Our focus on complex products is evidenced by our ability to gain approval for products such as HulioTM (adalimumab), Glatiramer Acetate, Semglee™, our insulin glargine, and OgivriTM (trastuzumab-dkst). In addition we remain focused on introducing additional biosimilars like Fulphila™ (pegfilgrastim) and rituximab.
We expect Mylan’s business in Europe to keep benefiting from our commercial platform, through which we simultaneously can serve multiple market types through multiple channels. Doing so allows us to focus on maximizing returns on investment by, for instance, repurposing branded drugs that lose exclusivity as tender or substitution products, or by switching from one proven strategy to another as individual government policies evolve, as is currently the case for biosimilars.
We look to maintain our leadership positions in markets such as France and Italy and prioritize opportunities in additional markets, such as Germany, Spain and the U.K.

11



Rest of World
Mylan’s commercial operations in Rest of World comprise a diverse group of businesses, many of which we believe have high growth potential. The Rest of World markets are attractive because of the growing middle class within these countries combined with an increase in the demand for pharmaceutical products. The highly competitive environment includes conditions like pricing and market access challenges, potential political instability, significant currency fluctuations and limited or changing availability of funding for healthcare.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-chart-486445a7963651de912.jpg
Mylan’s focus on becoming a leader in supplying antiretroviral medicines (“ARVs”) to treat HIV/AIDS has helped to increase our presence in many emerging market countries over the last decade.
Today approximately 40% of people being treated worldwide for the disease rely on one of our products. Most of these individuals live in countries that make up our Rest of World segment.
Many countries in this segment are brand-focused, and generic penetration is low. Our approximately 2,000 sales representatives are deployed in approximately 35 countries to promote our products. Among them are brands such as Amitiza®, Dona®, Creon®, Elidel® and Legalon®.
New product launches are an important growth driver. In accordance with our focus on complex products, we look forward to continuing to launch products such as Semglee™, ABEVMY® (bevacizumab) and OgivriTM (trastuzumab-dkst) into additional countries and introducing new medicines.
We look to maintain our leadership positions in countries such as Australia and Japan. We also are focused on maximizing opportunities in emerging markets like China, Brazil, India, Russia, Mexico, Turkey and Southeast Asia, where we see opportunity to introduce our existing global portfolio of products, especially our generics.
In addition, we have begun leveraging our ARV platform and expertise to help HIV patients in higher-income countries and to expand access to treatments for other infectious diseases, such as tuberculosis and malaria.
Refer to Note 15 Segment Information included in Item 8 in this Annual Report on Form 10-K for more information about our segments.
Government Regulation
Regulation by governmental authorities is a significant factor in the R&D, manufacture, marketing, sales and distribution of pharmaceuticals. Human therapeutic products are subject to rigorous preclinical and clinical testing to gather data to support approval, which requires extensive data and information; manufacturing is conducted under exacting conditions governed by extensive regulation; and post-approval activities, such as advertising and promotion and pharmacovigilance, are subject to pervasive regulation.
The lengthy process of developing products and obtaining required approvals and the continuing need for post-approval compliance with applicable statutes and regulations require the expenditure of substantial resources. Regulatory approval, if and when obtained, may be limited in scope. Further, approved drugs, as well as their manufacturers, are subject to

12



ongoing post-marketing review and inspection, which can lead to the discovery of previously unknown problems with products or the manufacturing or quality control procedures used in their production, which may result in restrictions on their manufacture, sale or use or in their withdrawal from the market.
Any failure or delay by us, our suppliers of manufactured drug product, collaborators or licensees, in obtaining regulatory approvals could adversely affect the marketing of our products and our ability to receive product revenue, license revenue or profit-sharing payments.
Other Regulatory Requirements
Our business is subject to a wide range of various other federal, state, non-governmental, and local agency rules and regulations. They focus on fraud and corruption, pricing and reimbursement, data privacy, and the environment, among many other considerations. For more information about certain of these regulations and the associated risks we face, see Item 1A. “Risk Factors” of this Annual Report on Form 10-K.
Research and Development
Mylan has a globally integrated R&D platform that is fueling our growth by filling our pipeline. We believe R&D always has been one of Mylan’s core strengths. Our Scientific Affairs team, which includes researchers and regulatory and clinical experts, numbers more than 3,000 people who work collaboratively across our 12 different R&D centers around the world, including 10 technology-focused development sites and 2 global R&D centers.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-increasingdeliverysystemcomp.jpg
Consistent with Mylan’s drive for durability, the allocation of our investments over the last several years has shifted away from commodity products, such as conventional oral solid dosage forms, to more complex or difficult-to-formulate products, such as biosimilars.
As a result, our product pipeline includes a variety of dosage forms. Collectively, these investments represent more than 3,000 products under development or pending approval around the world. Refer to the chart in the Business Segments section above for information pertaining to products in pipeline by major therapeutic area.

13



Collaboration and Licensing Agreements
We periodically enter into collaboration and licensing agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Doing so helps us share risks and costs, leverage strengths and scale up commercialization. The result often is that medicines become available sooner and to a significantly larger group of patients.
Our significant collaboration agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple, high-value generic biosimilar compounds, insulin analog products and respiratory products, among other complex products. Mylan’s significant collaboration and licensing agreements include those with Pfizer, Momenta Pharmaceuticals, Inc. (“Momenta”), Theravance Biopharma, Inc. (“Theravance Biopharma”), Biocon Ltd. (“Biocon”) and Fujifilm Kyowa Kirin Biologics Co. Ltd (“FKB”). Refer to Note 19 Collaboration and Licensing Agreements included in Item 8 in this Annual Report on Form 10-K for more information.
Intellectual Property
Mylan considers the protection of our intellectual property rights to be extremely valuable, and we act to protect them from infringement by third parties.
We have an extensive trademark portfolio and routinely apply to register key brand-name, generic, branded generic, biosimilars and OTC trade names in numerous countries around the world. Our registered trademarks are renewable indefinitely, and these registrations are properly maintained in accordance with the laws of the countries in which they are registered.
We also have an extensive patent portfolio and actively file for patent protection in various countries to protect our brand-name, generic, branded generic, biosimilars and OTC products, including processes for making and using them. We have more than 5,000 patents filed globally. For additional information, see “Risk Factors - We rely on the effectiveness of our patents, confidentiality agreements and other measures to protect our intellectual property rights.”
Further, we have well-established safeguards in place to protect our proprietary know-how and trade secrets, both of which we consider extremely valuable to our intellectual property portfolio.
We look for intellectual property licensing opportunities to or from third parties, related not only to our existing products, but as a means for expanding our product portfolio.
We rely on the aforementioned types of intellectual property, as well as our copyrights, regulatory exclusivities and contractual protections, to establish a broad scope of intellectual property rights for our product portfolio.
Exchange Act Reports
Mylan maintains a website at Mylan.com. We make available on or through it certain reports and associated amendments that the Company files with the Securities and Exchange Commission (“SEC”) in accordance with the Securities Exchange Act of 1934 (“Exchange Act”). Filings include our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports.
We make this information available on our website free of charge, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The contents of our website are not incorporated by reference in this Annual Report on Form 10-K and shall not be deemed “filed” under the Exchange Act.
The SEC also maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
ITEM 1A.
Risk Factors
We operate in a complex and rapidly changing environment that involves risks, many of which are beyond our control. Our business, financial condition, results of operations, cash flows, and/or share price could be materially affected by any of these risks, if they occur, or by other factors not currently known to us, or not currently considered to be material. These risk factors should be read in conjunction with the other information in this Annual Report on Form 10-K, as well as our other filings with the SEC. As discussed in Item 1. “Business” of this Annual Report on Form 10-K, Mylan, Pfizer, Upjohn and certain of their

14



affiliates have entered into a Business Combination Agreement pursuant to which they plan to effect the Combination. In addition to the risks described below, other risks related to the Combination, the Upjohn Business, the combined company’s business and Newco common stock are described in the registration statement on Form S-4, which has been filed by Upjohn with the SEC and subsequently amended, and declared effective on February 13, 2020, Form 10, which has been filed by Upjohn with the SEC and subsequently amended and has not yet been declared effective, and a definitive proxy statement of Mylan, which has been filed by Mylan on February 13, 2020.
Our risk factors are organized into five categories: Combination, Strategic, Operational, Compliance and Finance.
Combination Risks

Mylan, Pfizer and Upjohn may be unable to satisfy the conditions or obtain the approvals required to complete the Combination, and regulatory agencies may delay or impose conditions on approval of the Combination, which may diminish the anticipated benefits of the Combination. Failure to complete the Combination could adversely impact the market price of our shares as well as our business and operating results.

The consummation of the Combination is subject to the satisfaction (or, if applicable, valid waiver) of various conditions, including (a) the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder (the “HSR Act”) and the receipt of regulatory approvals in certain other jurisdictions, (b) the consummation of the Separation and the Distribution in accordance with the terms of the Separation Agreement (each as defined in Item 7 of this Annual Report on Form 10-K), (c) the approval of the Combination by Mylan shareholders, (d) the absence of any legal restraint (including legal actions or proceedings pursued by U.S. state authorities in the relevant states) preventing the consummation of the transactions, (e) in the case of Pfizer’s and Newco’s obligations to consummate the transactions, (i) the distribution of $12 billion in cash from Upjohn to Pfizer in accordance with the terms of the Separation Agreement and (ii) the receipt by Pfizer of a U.S. Internal Revenue Service (“IRS”) ruling and tax opinion of its tax counsel with respect to the Combination, and (f) other customary closing conditions. We cannot make any assurances that these conditions will be satisfied (or, if applicable, validly waived) in a timely manner or at all, in which case closing of the Combination may be delayed or may not occur and the benefits expected to result from the Combination may not be achieved. Any delay in the completion of the Combination could diminish anticipated benefits of the Combination or result in additional transaction costs, loss of revenue or other effects associated with uncertainty about the Combination.

To the extent that the market price of our ordinary shares reflects positive market assumptions that the Combination will be consummated, the price of our ordinary shares may decline if the Combination is not consummated for any reason or in a timely manner. We may also be subject to additional risks if the Combination is not consummated, including:

the requirement that we pay Pfizer a termination fee of $322 million if the Combination is not consummated because the Business Combination Agreement is terminated under certain circumstances;
the requirement that we must reimburse Pfizer up to $96 million of Pfizer’s reasonable out-of-pocket costs, fees and expenses in connection with the transactions, if our shareholders do not approve the Combination and the Business Combination Agreement is terminated by either Pfizer or us;
the fact that substantial costs related to the Combination incurred by us, such as legal, accounting, filing, financial advisory and financial printing fees, must be paid regardless of whether the Combination is consummated; and
possible negative reactions from our customers, regulators and employees.

The pendency of the Combination could adversely affect our business and operations.

Whether the Combination is ultimately consummated or not, its pendency could have a number of negative effects on our current business, including potentially disrupting our regular operations, diverting the attention of our workforce and management team, or increasing workforce turnover. The completion of the Combination, including, for example, obtaining regulatory approvals, will require significant time and attention from our management and may divert attention from the day-to-day operations of our business. Any uncertainty over the ability of Pfizer, us and Upjohn to complete the Combination could make it more difficult for us to retain key employees or attract new talent, or to pursue business strategies.

Parties with which we have business relationships, either contractual or operational, may experience uncertainty as to the future or desirability of such relationships and may delay or defer certain business decisions, seek alternative relationships with third parties or seek to alter their present business relationships with us. Parties with whom we otherwise may have sought to establish business relationships may seek alternative relationships with third parties. Additionally, we have contracts with certain

15



customers, suppliers, vendors, distributors, lenders, and other business partners, and these contracts may require us to obtain consent from these other parties in connection with the Combination. Obtaining such consents may be difficult and could impose costs on us, including renegotiating such contracts on terms less favorable to us, which in turn may result in us suffering a loss of potential future revenue, incurring contractual liabilities or losing rights that are material to our business.

The Business Combination Agreement subjects us to restrictions on certain of our business activities and obligates us to generally operate our business in the ordinary course in all material respects consistent with past practice prior to completion of the Combination. These restrictions could prevent us from pursuing attractive business opportunities that arise prior to the completion of the Combination and are outside the ordinary course of business, or otherwise have an adverse effect on our results of operations, cash flows and financial position. The Business Combination Agreement also subjects us to certain restrictions on our ability to solicit any alternative transaction proposal during the pendency of the Combination, although in certain circumstances we may make a change in recommendation in response to an unsolicited alternative transaction proposal that our board of directors determines is more favorable to us and our shareholders and other stakeholders than the Combination.

Strategic Risks
We do not anticipate paying dividends for the foreseeable future, and our shareholders must rely on increases in the trading price of our ordinary shares to obtain a return on their investment.
Mylan N.V. does not anticipate paying dividends in the immediate future. We anticipate that we will retain all earnings, if any, to support our operations and to opportunistically pursue additional transactions to deliver additional shareholder value. Any future determination as to the payment of dividends will, subject to Dutch law requirements, be at the sole discretion of our board of directors and will depend on our financial position, results of operations, capital requirements, and other factors our board of directors deems relevant at that time. Holders of Mylan N.V.’s ordinary shares must rely on increases in the trading price of their shares to obtain a return on their investment in the foreseeable future.
The market price of our ordinary shares may be volatile, and the value of your investment could materially decline.
Investors who hold Mylan N.V.’s ordinary shares may not be able to sell their shares at or above the price at which they purchased such shares. The share price of Mylan N.V.’s ordinary shares fluctuates materially from time to time, including significant declines in the past few years, and we cannot predict the price of our ordinary shares at any given time. The risks described herein could cause the price of our ordinary shares to fluctuate materially. In addition, the stock market in general, including the market for pharmaceutical companies, has experienced price and volume fluctuations. These broad market and industry factors may materially harm the market price of our ordinary shares, regardless of our operating performance. In addition, the price of our ordinary shares may be affected by the valuations and recommendations of the analysts who cover us, and if our results do not meet the analysts’ forecasts and expectations, the price of our ordinary shares could decline as a result of analysts lowering their valuations and recommendations or otherwise. Following periods of volatility in the market and/or in the price of a company’s stock, securities class-action litigation actions have been instituted against us and other companies. Such litigation has in the past and could in the future result in substantial costs and diversion of management’s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price. In addition, we or our shareholders also may offer or sell our ordinary shares or securities convertible into or exchangeable or exercisable for ordinary shares. An increase in the number of ordinary shares issued and outstanding and the possibility of sales of ordinary shares or securities convertible into or exchangeable or exercisable for ordinary shares may depress the future trading price of our ordinary shares. Furthermore, if additional offerings occur, the voting power of our then existing shareholders may be diluted.
Our strategic initiatives may not achieve all intended benefits.
There can be no assurance that our strategic initiatives will achieve their intended effects. We continually evaluate various strategic transactions and business arrangements, including acquisitions, asset purchases, partnerships, joint ventures, restructurings, divestitures, product rationalization, investments, market selection and market strategy on an ongoing basis. These transactions and arrangements may be material both from a strategic and financial perspective. There can be no assurance that we will be able to fully realize the expected benefits of any transactions or restructurings or successfully complete the integration of acquired businesses or assets. Furthermore, although our expectation is to engage in asset sales only if they advance or otherwise support our overall strategy, any such sale could reduce the size or scope of our business, our market share in particular markets or our opportunities with respect to certain markets, products or therapeutic categories. During the pendency of the Combination, these activities and initiatives are subject to applicable operating covenants set forth in the Business Combination Agreement and as discussed in “The pendency of the Combination could adversely affect our business and operations” above.

16



    The difficulties of achieving the benefits of strategic initiatives include, among others:
the diversion of management’s attention to integration matters and restructuring activities;
difficulties in achieving anticipated synergies, operating efficiencies, business opportunities, and growth prospects from restructuring or business transformation activities or business or asset combinations within the expected timeframe or at all;
difficulties in the integration of operations and information technology (“IT”) applications, including enterprise resource planning (“ERP”) systems;
difficulties in the integration of employees;
difficulties in managing the operations of a larger or more complex company;
challenges in keeping existing customers and obtaining new customers;
challenges in reducing reliance on transition services prior to the expiration of any period in which such services are provided by a transaction counterparty;
difficulties in obtaining a favorable price for any divestiture, in a timely manner or at all;
challenges in moving or rationalizing production facilities, including obtaining the consent of customers or regulatory authorities;
operational or financial difficulties that would not have occurred if acquired companies, businesses, or assets continued operating in their former structures;
challenges in attracting and retaining key personnel; and
the complexities of managing relationships with transaction counterparties and other business partners, including service agreements, development and manufacturing relationships, and license arrangements.
The overall execution of a strategic initiative, including the integration of a business or asset or restructuring activities, may result in material unanticipated problems, expenses, liabilities, competitive responses, loss of customer relationships, and diversion of management’s and/or employee’s attention, among other potential adverse consequences, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We may be adversely affected by significant scrutiny from third parties, including governments, or negative publicity with respect to matters relating to our products, pricing practices and other matters.
The Company has been subject to significant press coverage and scrutiny from third parties, including regulators, legislative bodies and enforcement agencies, with respect to matters relating to our business, pricing practices, and other matters. This coverage and public scrutiny have included assertions of wrongdoing against the Company which, regardless of the factual or legal basis for such assertions, have resulted in, and may continue to result in, investigations, and calls for investigations, by governmental agencies at both the federal and state levels, claims brought against the Company by governmental agencies or private parties, and regulators taking other measures that could have a negative effect on the Company’s business. For example, both the U.S. House of Representatives and the U.S. Senate have conducted hearings with respect to pharmaceutical drug pricing practices and alleged anti-competitive behavior by pharmaceutical companies, and additional hearings are likely. Ongoing focus on these issues has in the past led and in the future could lead to investigations of price increases and other business practices of specific pharmaceutical companies, including Mylan. It is not possible to predict the ultimate outcome of any such investigations or claims or what other investigations or lawsuits or regulatory responses may result from such assertions.
There has also recently been intense publicity regarding the pricing of pharmaceuticals more generally, including publicity and pressure resulting from prices charged by competitors and peer companies for new products as well as price increases by competitors and peer companies on older products that some have deemed excessive. We have experienced and may continue to experience downward pricing pressure on the price of certain of our products due to social or political pressure to lower the cost of drugs, which could reduce our revenue and future profitability.
Any of the above developments could result in reputational harm and reduced market acceptance and demand for our products, could harm our ability to market our products in the future, could cause us to incur significant expense, could cause our senior management to be distracted from execution of our business strategy, and could have a material adverse effect on our business, reputation, financial condition, results of operations, cash flows and/or ordinary share price.

17



We have and may continue to experience pressure on the pricing of and reimbursements for certain of our products due to consolidation among purchasers or social and political pressure to lower the cost of drugs.
We operate in a challenging environment, with significant pressures on the pricing of our products and on our ability to obtain and maintain satisfactory rates of reimbursement for our products by governments, insurers and other payors. The growth of overall healthcare costs has led governments and payors to implement new measures to control healthcare spending. As a result, we face numerous cost-containment measures by governments and other payors, including certain government-imposed industry-wide price reductions, mandatory rebates or pricing, international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries), volume-based procurement, tender systems, shifting of the payment burden to patients through higher co-payments, and requirements for increased transparency on pricing. In the U.S., certain of these pressures are further compounded by increasing consolidation among wholesalers, retailer drug chains, pharmacy benefit managers (“PBMs”), private insurers, managed care organizations and other private payors, which can increase their negotiating power, particularly with respect to our generic drugs. Please also refer to “A significant portion of our revenues is derived from sales to a limited number of customers.”
There has also been increasing U.S. federal and state legislative and enforcement interest with respect to drug pricing. In particular, U.S. federal prosecutors have issued subpoenas to pharmaceutical companies, including Mylan, seeking information about their drug pricing practices, among other issues, and members of the Congress have sought information from certain pharmaceutical companies, including Mylan, relating to drug-price increases.
In addition, there has been legislation and legislative proposals concerning drug prices and related issues, including the perceived need to bring more transparency to drug pricing, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs. For example, California, Oregon and several other states have recently implemented legislation requiring pharmaceutical companies to provide greater transparency with respect to drug prices and price increases and other states are considering similar legislation. In addition, Congress continues to consider drug pricing legislation that, if passed and signed into law, could impact companies’ ability to increase prices for prescription drugs. The current U.S. administration has also focused on lowering drug prices, through, for instance, the U.S. Department of Health and Human Services and FDA’s Safe Importation Action Plan announced in July 2019. These types of initiatives, at the federal or state level, could affect demand for, or pricing of, our products and we cannot predict what, if any, additional legislative developments may transpire or what the ultimate impact may be.
Any of the events or developments described above could have a material adverse impact on our business, reputation, financial condition, results of operations, cash flows and/or ordinary share price.
Current and changing economic conditions may adversely affect our industry, business, partners and suppliers.
The global economy continues to experience significant volatility, and the economic environment may become less favorable. Economic volatility, governmental financial restructuring efforts and evolving deficit and spending reduction programs could negatively impact the global economy and the pharmaceutical industry. This has led, or could lead, to reduced consumer and customer spending, reduced or eliminated governmental or third-party payor coverage or reimbursement or reduced spending on healthcare, including but not limited to pharmaceutical products. While generic drugs present an alternative to higher-priced branded products, our sales could be negatively impacted if patients forego obtaining healthcare, patients and customers reduce spending or purchases, or if governments or third-party payors reduce or eliminate coverage or reimbursement amounts for pharmaceuticals or impose price or other controls adversely impacting the price or availability of pharmaceuticals. In addition, reduced consumer and customer spending, reduced government or third-party payor coverage or reimbursement, or new government controls, may drive us and our competitors to decrease prices, may reduce the ability of customers to pay, or may result in reduced demand for our products. The occurrence of any of these risks could have a material adverse effect on our industry, business, financial condition, results of operations, cash flows, and/or ordinary share price.
We have significant operations globally, which exposes us to the risks inherent in conducting our business internationally.
Our operations extend to numerous countries globally, including our significant operations in India, and are subject to the risks inherent in conducting business globally and under the laws, regulations, and customs of various jurisdictions. These risks include, but are not limited to:
compliance with the national and local laws of countries in which we do business, including, but not limited to, data privacy and protection, import/export and intellectual property protections;

18



less established legal and regulatory regimes in certain jurisdictions, including with respect to the enforcement of intellectual property rights;
compliance with a variety of U.S. laws including, but not limited to, regulations put forth by the U.S. Treasury’s Office of Foreign Assets Control, the Iran Threat Reduction and Syria Human Rights Act of 2012 and rules relating to the use of certain “conflict minerals” under Section 1502 of the Dodd-Frank Wall Street Reform and the Consumer Protection Act;
changes in laws, regulations, and practices affecting the pharmaceutical industry and the healthcare system, including but not limited to imports, exports, manufacturing, quality, cost, pricing, reimbursement, approval, inspection, and delivery of healthcare;
changes in policies designed to promote foreign investment, including significant tax incentives, liberalized import and export duties, and preferential rules on foreign investment and repatriation;
increased Congressional scrutiny of overseas pharmaceutical manufacturing and
policy proposals related to increasing U.S. production of pharmaceutical products and API;
differing local product preferences and product requirements;
adverse changes in the economies in which we or our partners and suppliers operate as a result of a slowdown in overall growth, a change in government or economic policies, or financial, political, or social change or instability in such countries that affects the markets in which we operate, particularly emerging markets;
changes in employment laws, wage increases, or rising inflation in the countries in which we or our partners and suppliers operate;
supply disruptions and increases in energy and transportation costs;
increased tariffs on the import or export of our products or API, including on imports from China to the U.S.;
natural or man-made disasters, including droughts, floods, earthquakes, hurricanes and the impact of climate change in the countries in which we or our partners and suppliers operate;
local disturbances, the outbreak of highly contagious diseases or other health epidemics (such as coronavirus), terrorist attacks, riots, social disruption, wars, or regional hostilities in the countries in which we or our partners and suppliers operate and that could affect the economy, our operations and employees by disrupting operations and communications, making travel and the conduct of our business more difficult, and/or causing our customers to be concerned about our ability to meet their needs; and
government uncertainty, including as a result of new or changed laws and regulations.
We also face the risk that some of our competitors have more experience with operations in such countries or with international operations generally and may be able to manage unexpected crises more easily. Moreover, the internal political stability of, or the relationship between, any country or countries where we conduct business operations may deteriorate. Changes in a country’s political stability or the state of relations between any such countries are difficult to predict and the political or social stability in and/or diplomatic relations between any countries in which we or our partners and suppliers do business could meaningfully deteriorate.
For example, the formal change in the relationship between the European Union (“EU”) and the U.K. as a result of the U.K. referendum to leave the EU (“Brexit”) could impact our business. Pursuant to the withdrawal agreement between the U.K. and the EU, the U.K. formally withdrew from the EU on January 31, 2020 with status quo arrangements through a transition period. The transition period began on February 1, 2020 and is expected to last until December 31, 2020. While the Withdrawal Agreement provides for the possibility of one or more extensions of this transition period for up to two additional years, the United Kingdom has currently ruled out any such extension. During this transition period, the U.K. and the EU will negotiate a final agreement to govern their long-term relationship (the “Final Agreement”); however, if no agreement is reached before December 31, 2020 and no extension to the transition period is agreed to, a no-deal Brexit will occur on December 31, 2020.
Since Final Agreement negotiations are ongoing and a no-deal Brexit is still possible, the impact of Brexit on us remains uncertain. It continues to be the case that Brexit could lead to divergent national laws and regulations, import/export restrictions, and potential changes to intellectual property rights, regulatory approval requirements and pharmaceutical regulations in the EU and the U.K., which could materially impact the way we conduct our operations in those markets. In addition, because we are tax resident in the U.K., the U.K. withdrawal from the EU could, depending on the results of the ongoing Final Agreement negotiations, eliminate the benefit of certain tax treaties and tax-related EU directives. Any of these potential effects of Brexit, and others we cannot anticipate, could negatively affect our business and financial results.

19



In addition, in December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, Hubei Province, China. At the time of this filing, the outbreak has been largely concentrated in China, although cases have been confirmed in numerous other countries. In order to inhibit the spread of coronavirus, many manufacturing facilities throughout China have been shut down or are operating at lower capacities, which could impact the supply of API and other pharmaceutical product components from China. The extent to which the coronavirus impacts Mylan’s operations, including continued or increased disruptions to the supply chain, will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.
The occurrence of any one or more of the above risks could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial condition, results of operations, cash flows and/or ordinary share price.
Under accounting principles generally accepted in the U.S. (“U.S. GAAP”) relating to business acquisition accounting standards, we recognize the identifiable assets acquired, the liabilities assumed, and any noncontrolling interests in acquired companies generally at their acquisition date fair values and, in each case, separately from goodwill. Goodwill as of the acquisition date is measured as the excess amount of consideration transferred, which is also generally measured at fair value, and the net of the acquisition date amounts of the identifiable assets acquired and the liabilities assumed. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain. After we complete an acquisition, the following factors could result in material charges and adversely affect our operating results and may adversely affect our cash flows:
costs incurred to combine the operations of companies we acquire, such as transitional employee expenses and employee retention, redeployment or relocation expenses;
impairment of goodwill or intangible assets, including acquired in-process research and development (“IPR&D”);
amortization of intangible assets acquired;
a reduction in the useful lives of intangible assets acquired;
identification of or changes to assumed contingent liabilities, including, but not limited to, contingent purchase price consideration including fair value adjustments, income tax contingencies and other non-income tax contingencies, after our final determination of the amounts for these contingencies or the conclusion of the measurement period (generally up to one year from the acquisition date), whichever comes first;
charges to our operating results to eliminate certain duplicative pre-acquisition activities, to restructure our operations or to reduce our cost structure; and
charges to our operating results resulting from expenses incurred to effect the acquisition.
A significant portion of these adjustments could be accounted for as expenses that will decrease our net income and earnings per share for the periods in which those costs are incurred.
In particular, the amount of goodwill and identifiable intangible assets in our consolidated balance sheets is significant as a result of our acquisitions and other transactions, and may increase further following future potential acquisitions, and we may, from time to time, sell assets that we determine are not critical to our strategy or execution. Future events or decisions may also lead to asset impairments and/or related charges. Certain non-cash impairments may result from a change in our strategic goals, business direction or other factors relating to the overall business environment.
Any such charges could cause a material adverse effect on our business, financial condition, results of operations, cash flows, shareholders’ equity and/or ordinary share price.
The illegal distribution and sale by third parties of counterfeit versions of our products or of diverted or stolen products could have a negative impact on our reputation and our business.
The pharmaceutical drug supply has been increasingly challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet.
Third parties may illegally distribute and sell counterfeit versions of our products that do not meet the rigorous manufacturing and testing standards that our products undergo. Counterfeit products are frequently unsafe or ineffective and can

20



be potentially life-threatening. Counterfeit medicines may contain harmful substances, the wrong dose of API or no API at all. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version.
Reports of adverse reactions to counterfeit drugs or increased levels of counterfeiting could materially affect patient confidence in the authentic product. It is possible that adverse events caused by unsafe counterfeit products will mistakenly be attributed to the authentic product. In addition, unauthorized diversions of products or thefts of inventory at warehouses, plants, or while in-transit, which are not properly stored, or which are sold through unauthorized channels, could adversely impact patient safety, our reputation, and our business.
Public loss of confidence in the integrity of pharmaceutical products as a result of counterfeiting, diversion, or theft could have a material adverse effect on our business, reputation, financial condition, results of operations, cash flows, and/or ordinary share price.
We face vigorous competition that threatens the commercial acceptance and pricing of our products.
The pharmaceutical industry is highly competitive. We face competition from other pharmaceutical manufacturers globally, some of whom are significantly larger than we are. Our competitors may be able to develop products and processes competitive with or superior to our own for many reasons, including but not limited to the possibility that they may have:
proprietary processes or delivery systems;
larger or more productive R&D and marketing staff;
larger or more efficient production capabilities in a particular therapeutic area;
more experience in preclinical testing and human clinical trials;
more products; or
more experience in developing new drugs and greater financial resources, particularly with regard to manufacturers of branded products.
We also face increasing competition from lower-cost generic products and other branded products. Certain of our products are not protected by patent rights or have limited patent life and will soon lose patent protection. Loss of patent protection for a product typically is followed promptly with the launch of generic products. As a result, sales of many of these products may decline or stop growing over time. Various factors may result in the sales of certain of our products declining faster than has been projected. In addition, legislative proposals emerge from time to time in various jurisdictions to further encourage the early and rapid approval of generic drugs. Any such proposal that is enacted into law could increase competition and worsen this negative effect on our sales.
Competitors’ products may also be safer, more effective, more effectively marketed or sold, or have lower prices or better performance features than ours. We cannot predict with certainty the timing or impact of competitors’ products. PBMs and other pharmaceutical manufacturers may utilize contracting strategies that could decrease generic utilization and negatively impact our products. In addition, our sales may suffer as a result of changes in consumer demand for our products, including those related to fluctuations in consumer buying patterns tied to seasonality, importation by consumers or the introduction of new products by competitors.
The occurrence of any of the above risks could have an adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
A relatively small group of products may represent a significant portion of our revenues, net sales, gross profit, or net earnings from time to time.
Sales of a limited number of our products from time to time represent a significant portion of our revenues, net sales, gross profit, and net earnings. For the years ended December 31, 2019 and 2018, Mylan’s top ten products in terms of sales, in the aggregate, represented approximately 23% and 20%, respectively, of the Company’s net sales. If the volume or pricing of our largest selling products declines in the future, our business, financial condition, results of operations, cash flows, and/or ordinary share price could be materially adversely affected.

21



Our business could be negatively affected by the performance of our third-party collaboration partners.
We have entered into strategic alliances with partners to develop, manufacture, market and/or distribute certain products, and/or certain components of our products, in various markets. We commit substantial effort, funds and other resources to these various collaborations, including with respect to the development of biosimilar products. There is a risk that the investments made by us in these collaborative arrangements will not generate financial returns. While we believe our relationships with our partners generally are successful, disputes or conflicting priorities and regulatory or legal intervention could be a source of delay or uncertainty as to the expected benefits of the collaboration. In addition, we enter into agreements with our collaboration partners that provide for certain services, as well as cross manufacturing, development and licensing arrangements. A failure or inability of our partners to fulfill their collaboration obligations, or the occurrence of any of the risks above, could have an adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We may experience reductions in the levels of reimbursement for pharmaceutical products by governmental authorities, health maintenance organizations (“HMOs”), or other third-party payors. In addition, the use of tender systems and other forms of price control, including legislative or regulatory programs impacting pharmaceutical prices, could reduce prices for our products or reduce our market opportunities.
Various governmental authorities (including, among others, the U.K. National Health Service and the German statutory health insurance scheme) and private health insurers and other organizations, such as HMOs in the U.S., provide reimbursements or subsidies to consumers for the cost of certain pharmaceutical products. Demand for our products depends in part on the extent to which such reimbursement is available. In the U.S., third-party payors increasingly challenge the pricing of pharmaceutical products. These trends and other trends toward the growth of HMOs, managed healthcare, and legislative healthcare reform create significant uncertainties regarding the future levels of reimbursement for pharmaceutical products. Further, any reimbursement may be reduced in the future to the point that market demand for our products and/or our profitability declines. Such a decline could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
In addition, current or future U.S. federal, U.S. state or other countries’ laws and regulations may influence the prices of drugs and, therefore, could adversely affect the payments we receive for our products. For example, existing programs in certain U.S. states seek to broadly set prices within those states through the regulation and administration of the sale of prescription drugs. Expansion of these programs, and, in particular, changes to state Medicare and/or Medicaid programs, or changes required in the way in which Medicare payment rates are set and/or the way Medicaid rebates are calculated, could adversely affect the payment we receive for our products. In order to control expenditure on pharmaceuticals, most member states in the EU regulate the pricing of products and, in some cases, limit the range of different forms of pharmaceuticals available for prescription by national health services. These controls can result in considerable price differences between member states.
Several countries in which we operate have implemented, or plan to or may implement, government mandated price reductions and/or other controls. For example, China has implemented a volume-based procurement process and other measures designed to decrease prices for non-patented drug products. When such price controls occur, pharmaceutical companies have generally experienced significant declines in revenues and profitability and uncertainties continue to exist within the market after the price decrease. Such price reductions or controls could have an adverse effect on our business, and as uncertainties are resolved or if other countries in which we operate enact similar measures, they could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
A number of markets in which we operate have also implemented or may implement tender systems for generic pharmaceuticals in an effort to lower prices. Under such tender systems, manufacturers submit bids which establish prices for generic pharmaceutical products. Upon winning the tender, the winning company will receive a preferential reimbursement for a period of time. The tender system often results in companies underbidding one another by proposing low pricing in order to win the tender. Other markets may also consider the implementation of a tender system or other forms of price controls. Even if a tender system is ultimately not implemented, the anticipation of such could result in price reductions.
Failing to win tenders, or the implementation of similar systems or other forms of price controls in other markets leading to further price declines, could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Healthcare reform legislation could have a material adverse effect on our business.
In recent years, there have been numerous initiatives on the federal and state levels for comprehensive reforms affecting the payment for, the availability of and reimbursement for, healthcare services in the U.S., and it is likely that Congress and state

22



legislatures and health agencies will continue to focus on healthcare reform in the future. The Patient Protection and Affordable Care Act (“PPACA”) and The Health Care and Education and Reconciliation Act of 2010 (H.R. 4872), which amends the PPACA (collectively, the “Health Reform Laws”), were signed into law in March 2010. While the Health Reform Laws increased the number of patients who have insurance coverage for our products, they also included provisions such as the assessment of a pharmaceutical manufacturer fee and an increase in the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs. The Health Reform Laws continue to face uncertainty due to administrative efforts to repeal, substantially modify or invalidate some or all provisions of the Health Reform Laws, as well as challenges to their constitutionality. Further, Congress continues to consider drug pricing legislation that, if passed and signed into law, could impact companies’ ability to increase prices for products beyond the rate of inflation.
We are unable to predict the future course of federal or state healthcare legislation, including the outcome of challenges to such laws once passed. The Health Reform Laws and further changes in the law or regulatory framework that reduce our revenues or increase our costs could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Additionally, we encounter similar regulatory and legislative issues in most other countries. In the EU and some other international markets, the government provides healthcare at low cost to consumers and regulates pharmaceutical prices, patient eligibility and/or reimbursement levels to control costs for the government-sponsored healthcare system. These systems of price regulations may lead to inconsistent and lower prices. Within the EU and in other countries, the availability of our products in some markets at lower prices undermines our sales in other markets with higher prices. Additionally, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may also impair our ability to obtain acceptable prices in existing and potential new markets, and may create the opportunity for third party cross border trade.
Significant additional reforms to the U.S. or EU healthcare systems, or to the healthcare systems of other markets in which we operate, could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Provisions in our governance arrangements or that are otherwise available under Dutch law could discourage, delay, or prevent a change in control of us and may affect the market price of our ordinary shares.
Some provisions of our governance arrangements that are available under Dutch law, such as our grant to a Dutch foundation (stichting) of a call option to acquire preferred shares to safeguard the interests of the Company, its businesses and its stakeholders against threats to our strategy, mission, independence, continuity and/or identity, may discourage, delay, or prevent a change in control of us, even if such a change in control is sought by our shareholders.
The expansion of social media platforms presents new risks and challenges.
To the extent that we seek to use social media tools as a means to communicate about our products and/or business, there are uncertainties as to the rules that apply to such communications, or as to the interpretations that authorities will apply to the rules that exist. As a result, despite our efforts to monitor evolving social media communication guidelines and comply with applicable rules, there is risk that our use of social media for such purposes may cause us to be found in violation of them. Our employees may knowingly or inadvertently make use of social media tools in ways that may not be aligned with our social media strategy, may give rise to liability, or could lead to the loss of material non-public information, trade secrets or other intellectual property, or public exposure of personal information (including sensitive personal information) of our employees, clinical trial patients, customers, and others. In addition, negative posts or comments about us on any social media website could damage our reputation. Any of the above risks could have a material adverse effect on our business, reputation, financial condition, results of operations, cash flows, and/or ordinary share price.
Operational Risks
Our failure to comply with applicable environmental and occupational health and safety laws and regulations worldwide could adversely impact our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We are subject globally to various laws and regulations concerning, among other things, the environment, climate change, regulation of chemicals, employee safety and product safety. These requirements include regulation of the handling, manufacture, transportation, storage, use and disposal of materials, including the discharge of regulated materials and pollutants into the environment. In the normal course of our business, we are exposed to risks relating to possible releases of hazardous substances into the environment, which could cause environmental or property damage or personal injuries, and which could result in (i) our

23



noncompliance with such environmental and occupational health and safety laws and regulations and (ii) regulatory enforcement actions or claims for personal injury and property damage against us. If an unapproved environmental discharge occurs, or if we discover contamination caused by prior operations, including by prior owners and operators of properties we acquire, we could be liable for cleanup obligations, damages and fines. The substantial unexpected costs we may incur could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price. In addition, our environmental capital expenditures and costs for environmental compliance may increase substantially in the future as a result of changes in global environmental health and safety laws and regulations, the development and manufacturing of a new product or increased development or manufacturing activities at any of our facilities. We may be required to expend significant funds and our manufacturing activities could be delayed or suspended, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations.
The pharmaceutical industry is subject to regulation by various governmental authorities. For instance, we must comply with applicable laws and requirements of the FDA and other regulatory agencies, including foreign authorities, with respect to the research, development, manufacture, quality, safety, effectiveness, approval, labeling, tracking, tracing, authentication, storage, record-keeping, reporting, pharmacovigilance, sale, distribution, import, export, marketing, advertising, and promotion of pharmaceutical products. We are committed to conducting our business, including the sale and marketing of our products, in compliance with all applicable laws and regulations. These laws and regulations, however, are numerous and complex and it is possible that a governmental authority may challenge our activities, or that an employee or agent could violate these laws and regulations without our knowledge. Failure to comply with regulations of the FDA and other U.S. and foreign regulators could result in a range of consequences, including, but not limited to, fines, penalties, disgorgement, exclusion from U.S. federal healthcare reimbursement programs, unanticipated compliance expenditures, suspension of review of applications or other submissions, rejection or delay in approval of applications, recall or seizure of products, total or partial suspension of production and/or distribution, our inability to sell products, the return by customers of our products, injunctions, and/or criminal prosecution. Under certain circumstances, a regulator may also have the authority to revoke or vary previously granted drug approvals.
The safety profile of any product will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information about any of our marketed or investigational products, those authorities may require further inspections, enhancements to manufacturing controls, labeling changes, establishment of a risk evaluation and mitigation strategy or similar strategy, restrictions on a product’s indicated uses or marketing, or post-approval studies or post-market surveillance. In addition, we are subject to regulations in various jurisdictions, including the Federal Drug Supply Chain Security Act in the U.S., the Falsified Medicines Directive in the EU and several other such regulations in other countries that require us to develop electronic systems to serialize, track, trace and authenticate units of our products through the supply chain and distribution system. Compliance with these regulations has in the past and may in the future result in increased expenses for us or impose greater administrative burdens on our organization, and failure to meet these requirements could result in fines or other penalties.
The FDA and comparable regulatory authorities also regulate the facilities and operational procedures that we use to manufacture our products. We must register our facilities with the FDA and similar regulators in other countries. Products must be manufactured in our facilities in accordance with cGMP or similar standards in each territory in which we manufacture. Compliance with such regulations and with our own quality standards requires substantial expenditures of time, money, and effort in multiple areas, including training of personnel, record-keeping, production, and quality control and quality assurance. The FDA and other regulatory authorities, including foreign authorities, periodically inspect our manufacturing facilities for compliance with cGMP or similar standards in the applicable territory. Regulatory approval to manufacture a drug is granted on a site-specific basis. Failure to comply with cGMP and other regulatory standards at one of our or our partners’ or suppliers’ manufacturing facilities could result in an adverse action brought by the FDA or other regulatory authorities, which could result in a receipt of an untitled or warning letter, fines, penalties, disgorgement, unanticipated compliance expenditures, rejection or delay in approval of applications, suspension of review of applications or other submissions, suspension of ongoing clinical trials, recall or seizure of products, total or partial suspension of production and/or distribution, our inability to sell products, the return by customers of our products, orders to suspend, vary, or withdraw marketing authorizations, injunctions, consent decrees, requirements to modify promotional materials or issue corrective information to healthcare practitioners, refusal to permit import or export, criminal prosecution and/or other adverse actions.
If any regulatory body were to delay, withhold, or withdraw approval of an application; require a recall or other adverse product action; require one of our manufacturing facilities to cease or limit production; or suspend, vary, or withdraw related marketing authorization, our business could be adversely affected. Delay and cost in obtaining FDA or other regulatory approval

24



to manufacture at a different facility also could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Although we have established internal quality and regulatory compliance programs and policies, there is no guarantee that these programs and policies, as currently designed, will meet regulatory agency standards in the future or will prevent instances of non-compliance with applicable laws and regulations. Additionally, despite efforts at compliance, from time to time we or our partners receive notices of manufacturing and quality-related observations following inspections by regulatory authorities around the world, as well as official agency correspondence regarding compliance. For example, on November 5, 2019 the FDA issued a warning letter to Mylan’s API manufacturer Mylan Laboratories Limited Unit 8 relating to the manufacturing of valsartan API and nitrosamine impurities. Mylan has provided a thorough response to the FDA regarding the issues identified and remediation is ongoing. In addition, on November 9, 2018, the FDA issued a warning letter with respect to our manufacturing plant in Morgantown, West Virginia. This action resulted from previously disclosed observations of the plant made by FDA in April 2018. We have implemented comprehensive restructuring and remediation activities at our Morgantown plant, and the issues raised in the warning letter are being addressed within the context of these activities. However, we or our partners may receive similar observations and correspondence in the future. If we are unable to resolve these observations and address regulator’s concerns in a timely fashion, our business, financial condition, results of operations, cash flows, and/or ordinary share price could be materially affected.
We utilize controlled substances in certain of our current products and products in development, and therefore must meet the requirements of the Controlled Substances Act of 1970 and the related regulations administered by the Drug Enforcement Agency (“DEA”) in the U.S., as well as those of similar laws in other countries where we operate. These laws relate to the manufacture, shipment, storage, sale, and use of controlled substances. The DEA and other regulatory agencies limit the availability of the controlled substances used in certain of our current products and products in development and, as a result, our procurement quota of these active ingredients may not be sufficient to meet commercial demand or complete clinical trials. We must annually apply to the DEA and similar regulatory agencies for procurement quotas in order to obtain these substances. Any delay or refusal by the DEA or such similar agencies in establishing our procurement quota for controlled substances could delay or stop our clinical trials or product launches, or could cause trade inventory disruptions for those products that have already been launched. In addition, some states have passed laws and regulations imposing assessments on the sale or distribution of certain controlled substances, and other states are considering and may implement similar laws and regulations in the future. The occurrence of any of the above risks could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
The use of legal, regulatory, and legislative strategies by both brand and generic competitors, including but not limited to “authorized generics” and regulatory petitions, may increase costs associated with the introduction or marketing of our generic products, could delay or prevent such introduction, and could significantly reduce our revenue and profit.
Our competitors, both branded and generic, often pursue strategies to prevent or delay generic alternatives to branded products. These strategies include, but are not limited to:
entering into agreements whereby other generic companies will begin to market an authorized generic, which is the approved brand-name drug without the brand-name on its label, at the same time or after generic competition initially enters the market;
launching their own authorized generic product prior to or at the same time or after generic competition initially enters the market;
pricing a branded product at a discount equivalent to generic pricing, as was the case for Copaxone after the launch of our generic glatiramer acetate products;
filing petitions with the FDA or other regulatory bodies seeking to prevent or delay approvals, including timing the filings so as to thwart generic competition by causing delays of our product approvals;
contracting strategies among pharmaceutical manufacturers and PBMs that could decrease generic or biosimilar utilization and negatively impact our product launches;
seeking to establish regulatory and legal obstacles that would make it more difficult to demonstrate bioequivalence or to meet other requirements for approval, and/or to prevent regulatory agency review of applications;
initiating legislative or other efforts to limit the substitution of generic versions of brand pharmaceuticals;
filing suits for patent infringement and other claims that may delay or prevent regulatory approval, manufacture, and/or sale of generic products;
introducing “next-generation” products prior to the expiration of market exclusivity for the reference product, which often materially reduces the demand for the generic or the reference product for which we seek regulatory approval;

25



persuading regulatory bodies to withdraw the approval of brand-name drugs for which the patents are about to expire and converting the market to another product of the brand company on which longer patent protection exists;
obtaining extensions of market exclusivity by conducting clinical trials of brand drugs in pediatric populations or by other methods; and
seeking to obtain new patents on drugs for which patent protection is about to expire.
In the U.S., some companies have lobbied Congress for amendments to the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Act”) that would give them additional advantages over generic competitors. For example, although the term of a company’s drug patent can be extended to reflect a portion of the time a new drug application (“NDA”, which is filed in the U.S. with the FDA when approval is sought to market a newly developed branded product and, in certain instances, for a new dosage form, a new delivery system or a new indication for a previously approved drug) is under regulatory review, some companies have proposed extending the patent term by a full year for each year spent in clinical trials rather than the one-half year that is currently permitted.
If proposals like these in the U.S., Europe, or in other countries where we or our partners and suppliers operate were to become effective, or if any other actions by our competitors and other third parties to prevent or delay activities necessary to the approval, manufacture, or distribution of our products are successful, our entry into the market and our ability to generate revenues associated with new products may be delayed, reduced, or eliminated, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
If we are unable to successfully introduce new products in a timely manner, our future revenue and profitability may be adversely affected.
Our future revenues and profitability will depend, in part, upon our ability to successfully and timely develop, license, or otherwise acquire and commercialize new products. Product development is inherently risky, especially for new drugs for which safety and efficacy have not been established and/or the market is not yet proven as well as for complex generic drugs and biosimilars. Likewise, product licensing involves inherent risks, including, among others, uncertainties due to matters that may affect the achievement of milestones, as well as the possibility of contractual disagreements with regard to whether the supply of product meets certain specifications or terms such as license scope or termination rights. The development and commercialization process, particularly with regard to new and complex drugs, also requires substantial time, effort and financial resources. We, or a partner, may not be successful in commercializing such products on a timely basis, or at all, which could adversely affect our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Before any prescription drug product, including generic drug products, can be marketed, marketing authorization approval is required by the relevant regulatory authorities and/or national regulatory agencies (for example, the FDA in the U.S. and the EMA in the EU). The process of obtaining regulatory approval to manufacture and market new branded and generic pharmaceutical products is rigorous, time consuming, costly, and inherently unpredictable. In addition, these regulatory agencies may be delayed in reviewing and approving products as a result of lapsed or insufficient funding, insufficient staffing or other factors beyond our control. As a result of Brexit, the EU moved the headquarters of the EMA from the U.K. to the Netherlands in March 2019, which raises the possibility that any existing and/or new regulatory approval applications in the EU, whether for existing or new drug products, could be delayed as a result. Any delay in regulatory approval could impact the commercial or financial success of a product.
Outside the U.S., the approval process may be more or less rigorous, depending on the country, and the time required for approval may be longer or shorter than that required in the U.S. Bioequivalence, clinical, or other studies conducted in one country may not be accepted in other countries, the requirements for approval may differ among countries, and the approval of a pharmaceutical product in one country does not necessarily mean that the product will be approved in another country. We, or a partner or supplier, may be unable to obtain requisite approvals on a timely basis, or at all, for new products that we may develop, license or otherwise acquire. Moreover, if we obtain regulatory approval for a drug, it may be limited, for example, with respect to the indicated uses and delivery methods for which the drug may be marketed, or may include warnings, precautions or contraindications in the labeling, which could restrict our potential market for the drug. A regulatory approval may also include post-approval study or risk management requirements that may substantially increase the resources required to market the drug. Also, for products pending approval, we may obtain raw materials or produce batches of inventory to be used in efficacy and bioequivalence testing, as well as in anticipation of the product’s launch. In the event that regulatory approval is denied or delayed, we could be exposed to the risk of this inventory becoming obsolete.
The approval process for generic pharmaceutical products often results in the relevant regulatory agency granting final approval to a number of generic pharmaceutical products at the time a patent claim for a corresponding branded product or other market exclusivity expires. This often forces us to face immediate competition when we introduce a generic product into the

26



market. Additionally, further generic approvals often continue to be granted for a given product subsequent to the initial launch of the generic product. These circumstances generally result in significantly lower prices, as well as reduced margins, for generic products compared to branded products. New generic market entrants generally cause continued price, margin, and sales erosion over the generic product life cycle.
In the U.S., the Hatch-Waxman Act provides for a period of 180 days of generic marketing exclusivity for a “first applicant,” that is the first submitted Abbreviated New Drug Application (“ANDA”, which is filed in the U.S. with the FDA when approval is sought to market a generic equivalent of a drug product previously approved under an NDA and listed in the FDA publication entitled Approved Drug Products with Therapeutic Equivalence Evaluations, popularly known as the “Orange Book” or for a new dosage strength for a drug previously approved under an ANDA) containing a certification of invalidity, non-infringement or unenforceability related to a patent listed with the ANDA’s reference drug product, commonly referred to as a Paragraph IV certification. During this exclusivity period, which under certain circumstances may be shared with other ANDAs filed on the same day, the FDA cannot grant final approval to later-submitted ANDAs for the same generic equivalent. If an ANDA is awarded 180-day exclusivity, the applicant generally enjoys higher market share, net revenues, and gross margin for that generic product. However, our ability to obtain 180 days of generic marketing exclusivity may be dependent upon our ability to obtain FDA approval or tentative approval within an applicable time period of the FDA’s acceptance of our ANDA. If we are unable to obtain approval or tentative approval within that time period, we may risk forfeiture of such marketing exclusivity. By contrast, if we are not a “first applicant” to challenge a listed patent for such a product, we may lose significant advantages to a competitor with 180-day exclusivity, even if we obtain FDA approval for our generic drug product. The same would be true in situations where we are required to share our exclusivity period with other ANDA sponsors with Paragraph IV certifications.
In the EU and other countries and regions, there is no exclusivity period for the first generic product. The European Commission or national regulatory agencies may grant marketing authorizations to any number of generics.
If we are unable to navigate our products through the approval process in a timely manner, there could be an adverse effect on our product introduction plans, business, financial condition, results of operations, cash flows, and/or ordinary share price.
We expend a significant amount of resources on R&D efforts that may not lead to successful product introductions.
Much of our development effort is focused on technically difficult-to-formulate products and/or products that require advanced manufacturing technology, including our biosimilars program and respiratory platform. We conduct R&D primarily to enable us to gain approval for, manufacture, and market pharmaceuticals in accordance with applicable laws and regulations. We also partner with third parties to develop products. Typically, research expenses related to the development of innovative or complex compounds and the filing of marketing authorization applications for innovative and complex compounds (such as NDAs and biosimilar applications in the U.S.) are significantly greater than those expenses associated with the development of and filing of marketing authorization applications for most generic products (such as ANDAs in the U.S. and abridged applications in Europe). As we and our partners continue to develop new and/or complex products, our research expenses will likely increase. Because of the inherent risk associated with R&D efforts in our industry, including the high cost and uncertainty of conducting clinical trials (where required) particularly with respect to new and/or complex drugs, our, or a partner’s, R&D expenditures may not result in the successful introduction of new pharmaceutical products approved by the relevant regulatory bodies. Also, after we submit a marketing authorization application for a new compound or generic product, the relevant regulatory authority may change standards and/or request that we conduct additional studies or evaluations and, as a result, we may incur approval delays as well as R&D costs in excess of what we anticipated.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. We or our partners may experience delays in our ongoing or future clinical trials, and we do not know whether planned clinical trials will begin or enroll subjects on time, need to be redesigned, or be completed on schedule, if at all.
Clinical trials may be delayed, suspended or prematurely terminated for a variety of reasons. If we experience delays in the completion of, or the termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

27



Finally, we cannot be certain that any investment made in developing products will be recovered, even if we are successful in commercialization. To the extent that we expend significant resources on R&D efforts and are not able, ultimately, to introduce successful new and/or complex products as a result of those efforts, there could be a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Even if our products in development receive regulatory approval, such products may not achieve expected levels of market acceptance.
Even if we are able to obtain regulatory approvals for our new products, the success of those products is dependent upon market acceptance. Levels of market acceptance for our products could be impacted by several factors, including but not limited to:
the availability, perceived advantages, and relative safety and efficacy of alternative products from our competitors;
the degree to which the approved labeling supports promotional initiatives for commercial success;
the prices of our products relative to those of our competitors;
the timing of our market entry;
the effectiveness of our marketing, sales, and distribution strategy and operations; and
other competitor actions, including legal actions.
Additionally, studies of the proper utilization, safety, and efficacy of pharmaceutical products are being conducted by the industry, government agencies, and others. Such studies, which increasingly employ sophisticated methods and techniques, can call into question the utilization, safety, and efficacy of previously marketed as well as future products. In some cases, such studies have resulted, and may in the future result, in the discontinuation or variation of product marketing authorizations or requirements for risk management programs, such as a patient registry. Any of these events could adversely affect our profitability, business, financial condition, results of operations, cash flows, and/or ordinary share price.
The development, approval process, manufacture and commercialization of biosimilar products involve unique challenges and uncertainties, and our failure to successfully introduce biosimilar products could have a negative impact on our business and future operating results.
We and our partners and suppliers are actively working to develop and commercialize biosimilar products. Although the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) established a framework for the review and approval of biosimilar products and the FDA has begun to review and approve biosimilar product applications, there continues to be significant uncertainty regarding the regulatory pathway in the U.S., with the FDA continuing to issue and revise guidance related to its interpretation and implementation of the BPCIA. There is also uncertainty regarding the pathway to obtain approval for biosimilar products in other countries as well as uncertainty regarding the commercial pathway to successfully market and sell such products.
Moreover, biosimilar products generally involve extensive patent clearances and often involve patent infringement litigation related to multiple patents, which could delay or prevent the commercial launch of a biosimilar product for many years. If we are unable to obtain FDA or other non-U.S. regulatory authority approval for our products, we will be unable to market them. In addition, the development and manufacture of biosimilars pose unique challenges related to the supply of the materials needed to manufacture biosimilars. Access to and the supply of necessary biological materials may be limited, and government regulations restrict access to and regulate the transport and use of such materials.
Even if our biosimilar products are approved for marketing, the products may not be commercially successful, may require more time than expected to achieve market acceptance, and may not generate profits in amounts that are sufficient to offset the amount invested to obtain such approvals. Market success of biosimilar products will depend on demonstrating to regulators, patients, physicians and payors (such as insurance companies) that such products are safe and effective yet offer a more competitive price or other benefit over existing therapies. In addition, manufacturers of biologic products may try to dissuade physicians from prescribing or accepting biosimilar products. We may not be able to generate future sales of biosimilar products in certain jurisdictions and may not realize the anticipated benefits of our investments in the development, manufacture and sale of such products. If our development efforts do not result in the development and timely approval of biosimilar products or if such products, once developed and approved, are not commercially successful, or upon the occurrence of any of the above risks, our business, financial condition, results of operations, cash flows, and/or ordinary share price could be materially adversely affected.

28



Our business is highly dependent upon market perceptions of us, our products, and the safety and quality of our products, and may be adversely impacted by negative publicity or findings.
Market perceptions of us are very important to our business, especially market perceptions of our company, products and the safety and quality of our products. If we, our partners and suppliers, or our products suffer from negative publicity, or if any of our products or similar products which other companies distribute are subject to market withdrawal or recall or are proven to be, or are claimed to be, ineffective or harmful to consumers, then this could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price. Also, because we are dependent on market perceptions, negative publicity associated with product quality, patient illness, or other adverse effects resulting from, or perceived to be resulting from, our products, or our partners’ and suppliers’ manufacturing facilities, could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
A significant portion of our revenues is derived from sales to a limited number of customers.
A significant portion of our revenues is derived from sales to a limited number of customers. If we were to experience a significant reduction in or loss of business with one or more such customers, or if one or more such customers were to experience difficulty in paying us on a timely basis, our business, financial condition, results of operations, cash flows, and/or ordinary share price could be materially adversely affected.
In addition, a significant amount of our sales are to a relatively small number of drug wholesalers and retail drug chains. These customers represent an essential part of the distribution chain of generic pharmaceutical products. Drug wholesalers and retail drug chains have undergone, and are continuing to undergo, significant consolidation. This consolidation has resulted in these groups gaining additional purchasing leverage and, consequently, increasing the product pricing pressures facing our business. We expect this trend of increased pricing pressures to continue. Additionally, the emergence of large buying groups representing independent retail pharmacies and the prevalence and influence of managed care organizations and similar institutions increases the negotiating power of these groups, enabling them to attempt to extract price discounts, rebates, and other restrictive pricing terms on our products. These factors could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
During the years ended December 31, 2019, 2018 and 2017, Mylan’s consolidated net sales to its three largest customers were approximately: 8%, 8%, and 10%, respectively, to Cardinal Health, Inc.; 15%, 12%, and 13%, respectively, to McKesson Corporation; and 9%, 8%, and 8%, respectively, to AmerisourceBergen Corporation.
The supply of API into Europe may be negatively affected by recent regulations promulgated by the EU.
All API imported into the EU has needed to be certified as complying with the good manufacturing practice standards established by the EU laws and guidance, as stipulated by the International Conference for Harmonization. These regulations place the certification requirement on the regulatory bodies of the exporting countries. Accordingly, the national regulatory authorities of each exporting country must: (i) ensure that all manufacturing plants within their borders that export API into the EU comply with EU manufacturing standards and (ii) for each API exported, present a written document confirming that the exporting plant conforms to EU manufacturing standards. The imposition of this responsibility on the governments of the nations exporting an API may cause delays in delivery or shortages of an API necessary to manufacture our products, as certain governments may not be willing or able to comply with the regulation in a timely fashion, or at all. A shortage in API may prevent us from manufacturing, or cause us to have to cease manufacture of, certain products, or to incur costs and delays to qualify other suppliers to substitute for those API manufacturers unable to export. The occurrence of any of the above risks could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We have a limited number of manufacturing facilities and certain third-party suppliers produce a substantial portion of our API and products, some of which require a highly exacting and complex manufacturing process.
A substantial portion of our capacity, as well as our current production, is attributable to a limited number of manufacturing facilities and certain third-party suppliers. A significant disruption at any one of such facilities within our internal or third-party supply chain, even on a short-term basis, whether due to the failure of a third-party supplier to fulfill the terms of their agreement with us, labor disruption, adverse quality or compliance observation, other regulatory action, infringement of brand or other third-party intellectual property rights, natural disaster, civil or political unrest, export or import restrictions, or other events could impair our ability to produce and ship products to the market on a timely basis and could, among other consequences, subject us to exposure to claims from customers. Any of these events could have a material adverse effect on our reputation, business, financial condition, results of operations, cash flows, and/or ordinary share price. If we or our third-party suppliers’ face significant manufacturing issues, this could lead to shutdowns or product shortages, or to our being entirely unable to supply certain products

29



to customers for an extended period of time. Such shortages or shutdowns have led and could continue to lead to significant losses of sales revenue, third-party litigation, or negative publicity. See also “The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations.”
We purchase certain API and other materials and supplies that we use in our manufacturing operations, as well as certain finished products, from many different foreign and domestic suppliers. The price of API and other materials and supplies is subject to volatility, and in certain cases, we have listed only one supplier in our applications with regulatory agencies. There is no guarantee that we will always have timely, sufficient or affordable access to critical raw materials or finished product supplied by third parties, even when we have more than one supplier, which could lead to our or our partners’ and suppliers’ inability to supply sufficient quantities of our products to meet market demand. In addition, quality deficiencies in the products which we or our suppliers provide, or at our or their manufacturing facilities, have in the past and could in the future adversely impact our manufacturing and supply capabilities, cause supply interruptions, or lead to voluntary market withdrawals or product recalls. An increase in the price, or an interruption in the supply, of a single-sourced or any other raw material, including the relevant API, or in the supply of finished product, could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
In addition, the manufacture of some of our products is a highly exacting and complex process, due in part to strict regulatory requirements. Problems may arise during manufacturing at our or our third-party suppliers’ facilities for a variety of reasons, including, among others, equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, natural disasters, power outages, labor unrest, and environmental factors. If problems arise during the production of a batch of product, that batch of product may have to be discarded. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, time and expense spent investigating the cause, and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred.
If we or one of our suppliers experience any of the problems described above, such problems could have a material adverse effect on our reputation, business, financial condition, results of operations, cash flows, and/or ordinary share price.
Our future success is highly dependent on our continued ability to attract and retain key personnel.
It is important that we attract and retain qualified personnel in order to develop and commercialize new products, manage our business, and compete effectively. Competition for qualified personnel in the pharmaceutical industry is very intense. If we fail to attract, develop, incentivize and retain key scientific, technical, commercial, regulatory or management personnel, this could lead to loss of customers, business disruption, and a decline in revenues, adversely affect the progress of pipeline products, or otherwise adversely affect our operations. Additionally, while we work to ensure that we have effective plans in place for management succession, any anticipated or unanticipated management transition could create uncertainty, which could disrupt or result in changes to our strategy and have a negative impact on our business. While we have employment agreements with certain key employees in place, their employment for the duration of the agreement is not guaranteed. Current and prospective employees might also experience uncertainty about their future roles with us following the consummation and/or integration of recent acquisitions, the Combination, and potential future transactions, which might adversely affect our ability to retain key managers and other employees. If we are unsuccessful in retaining our key employees or enforcing certain post-employment contractual provisions such as confidentiality or non-competition provisions, it could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We are in the process of enhancing and further developing our global ERP systems and associated business applications, which could result in business interruptions if we encounter difficulties.
We are enhancing and further developing our global ERP and other business critical IT infrastructure systems and associated applications to provide more operating efficiencies and effective management of our business and financial operations. Such changes to ERP systems and related software, and other IT infrastructure carry risks such as cost overruns, project delays and business interruptions and delays. If we experience a material business interruption as a result of our ERP enhancements, it could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Compliance Risks

30



We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties.
We are subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-corruption laws in other jurisdictions. These laws generally prohibit companies and their intermediaries from engaging in bribery or making other prohibited payments to government officials for the purpose of obtaining or retaining business, and some have record keeping requirements. The failure to comply with these laws could result in substantial criminal and/or monetary penalties. We operate in jurisdictions that have experienced corruption, bribery, pay-offs and other similar practices from time-to-time and, in certain circumstances, such practices may be local custom. We have implemented and trained relevant employees regarding internal control policies and procedures that mandate compliance with these anti-corruption laws. However, we cannot be certain that these policies and procedures will protect us against liability. There can be no assurance that our employees or other agents will not engage in such conduct for which we might be held responsible. If our employees or agents are found to have engaged in such practices, we could suffer severe criminal or civil penalties and other consequences that could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Our competitors, including branded pharmaceutical companies, and/or other third parties, may allege that we or our suppliers are infringing upon their intellectual property, including in an “at risk launch” situation, which could result in substantial monetary damages, impact our ability to launch a product and/or our ability to continue marketing a product, and/or force us to expend substantial resources in resulting litigation, the outcome of which is uncertain.
Companies that produce branded pharmaceutical products and other patent holders routinely bring litigation against entities selling or seeking regulatory approval to manufacture and market generic forms of their branded products, as well as other entities involved in the manufacture, supply, and other aspects relating to API and finished pharmaceutical products. These companies and other patent holders may allege patent infringement or other violations of intellectual property rights as the basis for filing suit against an applicant for a generic product as well as others who may be involved in some aspect of research, supply, production, distribution, testing, packaging or other processes. Litigation often involves significant expense and can delay or prevent introduction or sale of our generic products. If patents are held valid and infringed by our products in a particular jurisdiction, we and/or our supplier(s) or partner(s) may, unless we or the supplier(s) or partner(s) could obtain a license from the patent holder, need to cease manufacturing and other activities, including but not limited to selling in that jurisdiction. We may also need to pay damages, surrender or withdraw the product, or destroy existing stock in that jurisdiction.
There also may be situations, such as the decision to launch our 40mg/mL glatiramer acetate and Fulphila products, where we use our business judgment and decide to market and sell products directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) and other third-party rights have not been finally resolved by the courts (i.e., an “at-risk launch”). The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, among other things, a reasonable royalty on sales, damages measured by the profits lost by the patent holder, or by profits earned by the infringer. If there is a finding by a court of willful infringement, the definition of which is subjective, such damages may be increased by up to three times. Moreover, because of the discount pricing typically involved with bioequivalent products, patented branded products generally realize a substantially higher profit margin than generic or biosimilar products. An adverse decision in a case such as this, or a judicial order preventing us or our suppliers and partners from manufacturing, marketing, selling, and/or other activities necessary to the manufacture and distribution of our products, could result in substantial penalties, and/or have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We rely on the effectiveness of our patents, trademarks, confidentiality agreements and other measures to protect our intellectual property rights.
Our ability to commercialize any branded product successfully will largely depend upon our or any partner’s or supplier’s ability to obtain, maintain and enforce patents and trademarks of sufficient scope to lawfully prevent third parties from developing and/or marketing infringing products. In the absence of adequate intellectual property protections or other barriers to entry, competitors may adversely affect our branded products business by independently developing and/or marketing substantially equivalent products. It is also possible that we could incur substantial costs if we initiate litigation against others to protect or enforce our intellectual property rights.
We may file patent filings covering the API, formulation, methods of making, and/or methods of using for our branded products and branded product candidates. We may not be issued patents based on patent applications already filed or that we file in the future. Further, due to other factors that affect patentability, and if patents are issued, they may be insufficient in scope to cover or otherwise protect our branded products. Patents are national in scope and therefore the issuance of a patent in one country does not ensure the issuance of a patent in any other country. Furthermore, the patent position of companies in the pharmaceutical

31



industry generally involves complex legal and factual questions and has been and remains the subject of significant litigation. Legal standards relating to scope and validity of patent claims are evolving and may differ in various countries. Any patents we have obtained, or obtain in the future, may be challenged, invalidated or circumvented. Moreover, the U.S. Patent and Trademark Office or any other governmental agency may commence inter partes review or interference proceedings involving, or consider other challenges to, our patents or patent applications. In addition, branded products often have market viability based upon the goodwill of the product name, which typically benefits from trademark protection. Our branded products may therefore also be subject to risks related to the loss of trademark or patent protection or to competition from generic or other branded products. Challenges can come from other businesses, individuals or governments, and governments could require compulsory licensing of this intellectual property. Any challenge to, or invalidation or circumvention of, our intellectual property (including patents or patent applications, copyrights and trademark protection) would be costly, would require significant time and attention of our management, and could cause a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We also rely on trade secrets, unpatented proprietary know-how, trademarks, trade dress, regulatory exclusivity and continuing technological innovation that we seek to protect, in part by confidentiality agreements with licensees, suppliers, employees and consultants. These measures may not provide adequate protection for our unpatented technology. If these agreements are breached, it is possible that we will not have adequate remedies. Disputes may arise concerning the ownership of intellectual property or the applicability of confidentiality agreements. Furthermore, our trade secrets and proprietary technology may otherwise become known or be independently developed by our competitors or we may not be able to maintain the confidentiality of information relating to such products.
Our ability to enforce intellectual property rights also depends on the laws of individual countries, each country’s practices with respect to enforcement of intellectual property rights, and the extent to which certain countries may seek to engage in policies or practices that may weaken its intellectual property framework (e.g., a policy of routine compulsory licensing, or threat of compulsory licensing, of pharmaceutical intellectual property). If we are unable to adequately protect our technology, trade secrets or proprietary know-how, or enforce our intellectual property rights, this could cause a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Our reporting and payment obligations related to our participation in U.S. federal healthcare programs, including Medicare, Medicaid and the Department of Veterans Affairs (the “VA”), are complex and often involve subjective decisions that could change as a result of new business circumstances, new regulations or agency guidance, or advice of legal counsel. Any failure to comply with those obligations could subject us to investigation, penalties, and sanctions.
U.S. federal laws regarding reporting and payment obligations with respect to a pharmaceutical company’s participation in federal healthcare programs, including Medicare, Medicaid and the VA, are complex. Because our processes for calculating applicable government prices and the judgments involved in making these calculations involve subjective decisions and complex methodologies, these calculations are subject to risk of errors and differing interpretations. In addition, they are subject to review and challenge by the applicable governmental agencies, and it is possible that such reviews could result in changes that may have material adverse legal, regulatory, or economic consequences.
Pharmaceutical manufacturers that participate in the Medicaid Drug Rebate Program, such as Mylan, are required to report certain pricing data to the Centers for Medicare & Medicaid Services (“CMS”), the federal agency that administers the Medicare and Medicaid programs. This data includes the Average Manufacturer Price (“AMP”) for each of the manufacturer’s covered outpatient drugs. CMS calculates a type of U.S. federal ceiling on reimbursement rates to pharmacies for multiple source drugs under the Medicaid program, known as the federal upper limit (“FUL”). Since April 2016, CMS is required to use the weighted average AMP for pharmaceutically and therapeutically equivalent multiple source drugs to calculate FULs, instead of the other pricing data CMS previously used. Although weighted average AMP-based FULs do not reveal Mylan’s individual AMP, publishing a weighted average AMP available to customers and the public at large could negatively affect our commercial price negotiations.
In addition, a number of state and federal government agencies are conducting investigations of manufacturers’ reporting practices with respect to Average Wholesale Prices (“AWP”). The government has alleged that reporting of inflated AWP has led to excessive payments for prescription drugs, and we may be named as a defendant in actions relating to pharmaceutical pricing issues and whether allegedly improper actions by pharmaceutical manufacturers led to excessive payments by Medicare, Medicaid and/or the VA.
Any governmental agencies or authorities that have commenced, or may commence, an investigation of us relating to the sales, marketing, pricing, quality, or manufacturing of pharmaceutical products could seek to impose, based on a claim of violation of anti-fraud and false claims laws or otherwise, civil and/or criminal sanctions, including fines, penalties, and possible

32



exclusion from federal healthcare programs, including Medicare, Medicaid and/or the VA. Some of the applicable laws may impose liability even in the absence of specific intent to defraud. Furthermore, should there be ambiguity with regard to how to properly calculate and report payments - and even in the absence of any such ambiguity - a governmental authority may take a position contrary to a position we have taken, and may impose or pursue civil and/or criminal sanctions. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. There can be no assurance that our submissions will not be found by CMS or the VA to be incomplete or incorrect. Any failure to comply with the above laws and regulations, and any such penalties or sanctions could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We are involved in various legal proceedings and certain government inquiries and may experience unfavorable outcomes of such proceedings or inquiries.
We are or may be involved in various legal proceedings and certain government inquiries or investigations, including, but not limited to, patent infringement, product liability, claims with respect to the manufacture, sale marketing and distribution of opioid products, antitrust matters, breach of contract, and claims involving Medicare, Medicaid and/or VA reimbursements, or laws relating to sales, marketing, and pricing practices, some of which are described in our periodic reports, that involve claims for, or the possibility of, fines and penalties involving substantial amounts of money or other relief, including but not limited to civil or criminal fines and penalties and exclusion from participation in various government healthcare-related programs. With respect to government enforcement of state and federal laws, including antitrust laws, as well as private plaintiff litigation of so-called “pay for delay” patent settlements, large verdicts, settlements or government fines are possible, especially in the U.S. and EU. In addition, after the consummation of the Combination, Newco has agreed to pay Pfizer an amount equal to 57% of any losses actually incurred or suffered by Mylan, Newco or their respective subsidiaries, since the date of the Business Combination Agreement, arising out of third-party actions relating to the manufacture, distribution, marketing, promotion or sale of opioids by or on behalf of Mylan or its subsidiaries. If any of these legal proceedings or inquiries were to result in an adverse outcome, the impact could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price. Refer to Note 20 Litigation included in Item 8 in this Annual Report on Form 10-K for further discussion of litigation matters.
Emerging developments in the U.S. legal landscape relative to the liability of generic pharmaceutical manufacturers for certain product liabilities claims could increase our exposure to litigation costs and damages. Although we maintain a combination of self-insurance and commercial insurance, no reasonable amount of insurance can fully protect against all risks because of the potential liability inherent in the business of producing pharmaceuticals for human consumption. To the extent that a loss occurs, depending on the nature of the loss and the level of insurance coverage maintained, it could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
In addition, in limited circumstances, entities that we have acquired are party to litigation in matters under which we are, or may be, entitled to indemnification by the previous owners. Even in the case of indemnification, there are risks inherent in such indemnities and, accordingly, there can be no assurance that we will receive the full benefits of such indemnification, or that we will not experience an adverse result in a matter that is not indemnified, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
If we fail to comply with our corporate integrity agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs.
In August 2017, Mylan Inc. and Mylan Specialty L.P. entered into a Corporate Integrity Agreement (the “CIA”) with the Office of Inspector General of the Department of Health and Human Services (“OIG-HHS”). The CIA has a five-year term and requires, among other things, enhancements to our compliance program, fulfillment of reporting and monitoring obligations, management certifications and resolutions from Mylan Inc.’s board, as well as that an independent review organization annually review various matters relating to the Medicaid Drug Rebate Program, among other things. If we fail to comply with the CIA, the OIG-HHS may impose substantial monetary penalties or exclude us from federal healthcare programs, including Medicare, Medicaid or the VA, which could have a material adverse effect on our business, financial condition and results of operations.
We are increasingly dependent on IT and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
Significant disruptions to our IT systems or breaches of information security could adversely affect our business. We are increasingly dependent on sophisticated IT systems and infrastructure to operate our business. We also have outsourced significant elements of our operations to third parties, some of which are outside the U.S., including significant elements of our IT infrastructure, and as a result we are managing many independent vendor relationships with third parties who may or could have access to our

33



confidential information. The size and complexity of our IT systems, and those of our third-party vendors with whom we contract, make such systems potentially vulnerable to service interruptions. In addition, we and our vendors have experienced and expect to continue to experience phishing attempts, firewall and business email compromises and other third-party attacks on our or our vendors’ IT systems, networks and infrastructures. Such attacks are increasingly sophisticated and are made by groups and individuals with a wide range of motives and expertise, including state and quasi-state actors, criminal groups, “hackers” and others. Any security breach or other disruption to our or our vendors’ IT infrastructure could also interfere with or disrupt our business operations, including our manufacturing, distribution, R&D, sales and/or marketing activities.
In the ordinary course of business, we and our vendors collect, store and transmit large amounts of confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and it is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. The size and complexity of our and our vendors’ systems and the large amounts of confidential information that is present on them also makes them potentially vulnerable to security breaches from inadvertent or intentional actions by our employees, partners or vendors, or from attacks by malicious third parties. Maintaining the security, confidentiality and integrity of this confidential information (including trade secrets or other intellectual property, proprietary business information and personal information) is important to our competitive business position. However, such information can be difficult to protect. While we have taken steps to protect such information, and to ensure that the third-party vendors’ on which we rely have taken adequate steps to protect such information, there can be no assurance that our or our vendors’ efforts will prevent service interruptions or security breaches in our systems or the unauthorized or inadvertent wrongful use or disclosure of confidential or material non-public information that could adversely affect our business operations or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information.
A breach of our or our vendors’ security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information, or other confidential information, whether as a result of theft, hacking, fraud, trickery or other forms of deception, or for any other cause, could enable others to produce competing products, use our proprietary technology or information, and/or adversely affect our business position. Further, any such interruption, security breach, or loss, misappropriation, and/or unauthorized access, use or disclosure of confidential information, including personal information regarding our patients and employees, could result in financial, legal, business, and reputational harm to us and could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We are subject to data privacy and security laws and regulations in many different jurisdictions and countries where we do business, and our or our vendors’ inability to comply could result in fines, penalties, reputational damage, and could impact the way we operate our business.
We are subject to federal, state and international data privacy and security laws and regulations governing the collection, use, disclosure, transmission and protection of personal information, including health-related information. As the legislative and regulatory landscape for data privacy and security continues to evolve around the world, there has been an increasing focus on data privacy and security matters that may affect our business.
In the U.S., the federal Health Insurance Portability and Accountability Act of 1996, and the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”) governs the use, disclosure, and security of protected health information by HIPAA covered entities and business associates. Several U.S. states have enacted, or proposed, data privacy laws and regulations governing the confidentiality, security, use and disclosure of personal information, which may impose greater restrictions than federal data privacy and security laws and regulations. For example, the California Consumer Privacy Act of 2018 (“CCPA”) was signed into law on June 28, 2018 and became effective on January 1, 2020. The CCPA grants new rights to California consumers, including, among others, the right to know what personal information is collected, used, shared, or sold and a right to deletion of personal information held by businesses and businesses’ service providers. We may also be subject to other state data privacy and security breach notification laws, state health information privacy laws, and federal and state consumer protection laws which impose requirements for the collection, use, disclosure, transmission and protection of personal information. Each of these laws are subject to varying interpretations by courts and regulatory or government agencies, creating complex compliance issues for us. If we, or the third-party vendors on which we rely, fail to comply with applicable laws and regulations we could be subject to fines, penalties or sanctions, including criminal penalties.
Outside of the U.S., data protection laws, including the EU’s General Data Protection Regulation (“GDPR”), EU member states implementing regulations, and other jurisdictional data protection laws and regulations impose significant compliance obligations on our organization. The GDPR became effective in EU member states on May 25, 2018. The GDPR contains data protection requirements in the EU and imposes a framework of obligations and restrictions governing the collection, processing, and the transmission of personal data to jurisdictions outside of the EU. The GDPR affords individuals with a series of privacy rights related to the collection, processing, and transmission of their personal data. The GDPR imposes significant compliance

34



obligations, including required processes and policies governing our collection, transmission, processing and use of individuals personal data. In addition, the GDPR includes significant penalties for non-compliance, with fines up to the higher of €20 million or 4% of total annual worldwide revenue. In general, GDPR, and other data protection laws and regulations, could require adaptation of our technologies or practices to satisfy local country data protection requirements and standards.
Other countries in which we operate, including Australia, Canada, China, India, Japan, Russia and South Africa, have, or are developing, laws and regulations governing the collection, use, securing and transmission of personal information as well that may affect our business or require us to adapt our technologies or practices. Most recently, Brazil enacted significant data privacy legislation, the Lei Geral de Protecaode Dados, which becomes effective in August 2020. Some countries, including India and Russia, are considering legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements.
These and similar initiatives could increase the cost of developing, implementing or maintaining our IT systems, require us to allocate more resources to compliance initiatives or increase our costs. In addition, a failure by us, or our third-party vendors, to comply with applicable data privacy and security laws may lead to government enforcement actions and private litigation, which could result in financial, legal, business, and reputational harm to us and could have a material adverse effect on the way we operate our business, our financial condition, results of operations, cash flows, and/or ordinary share price.
Increasing scrutiny and evolving expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.
Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance practices and disclosure. Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, health and safety, supply chain management, diversity and human rights. Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation and the price of our ordinary shares.
In addition, a number of our customers, including certain government purchasers, have adopted, or may adopt, procurement policies that include social and environmental requirements, including, for example, requirements to conduct third party audits, or these customers may seek to include such provisions in their procurement contract terms and conditions. These social and environmental responsibility provisions and initiatives are subject to change, vary from jurisdiction to jurisdiction, and certain elements may be difficult and/or cost prohibitive for us to comply with given the inherent complexity of our external supply chain and the global scope of our operations. In certain circumstances, in order to meet the requirements or standards of our customers, we may be obligated to modify our sourcing practices or make other operational choices which may require additional investments and increase our costs or result in inefficiencies. Alternatively, we may be ineligible to participate in bids or tenders in certain markets, which may result in lost sales and revenues.
Any of the factors mentioned above, or the perception that we or our suppliers or contract manufacturers have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, financial condition, results of operations cash flows and/or ordinary share price.
Finance Risks
If the intercompany terms of cross border arrangements that we have among our subsidiaries are determined to be inappropriate or ineffective, our tax liability may increase.
We have potential tax exposures resulting from the varying application of statutes, regulations, and interpretations which include exposures on intercompany terms of cross-border arrangements among our subsidiaries (including intercompany loans, sales, and services agreements) in relation to various aspects of our business, including manufacturing, marketing, sales, and delivery functions. Although we believe our cross-border arrangements among our subsidiaries are based upon internationally accepted standards and applicable law, tax authorities in various jurisdictions may disagree with and subsequently challenge the amount of profits taxed in their country, which may result in increased tax liability, including accrued interest and penalties, which would cause our tax expense to increase and could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.

35



We may not be able to maintain competitive financial flexibility and our corporate tax rate which could adversely affect us and our shareholders.
We believe that our structure and operations give us the ability to achieve competitive financial flexibility and a competitive worldwide effective corporate tax rate. We must make material assumptions underlying our expected tax rates, including regarding the effect of certain internal reorganization transactions, including various intercompany transactions. We cannot give any assurance as to what our effective tax rate will be, however, because of, among other reasons, uncertainty regarding the tax policies of the jurisdictions where we operate, potential changes of laws and interpretations thereof, and the potential for tax audits or challenges. Our actual effective tax rate may vary from our expectation and that variance may be material. Additionally, the tax laws of the U.K., the Netherlands and other jurisdictions could change in the future, and such changes could cause a material change in our effective tax rate.
Any of the factors discussed above could materially increase our overall effective income tax rate and income tax expense and could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Unanticipated changes in our tax provisions or exposure to additional income tax liabilities and changes in income tax laws and tax rulings may have a significant adverse impact on our effective tax rate and income tax expense.
We are subject to income taxes in many jurisdictions. Significant analysis and judgment are required in determining our worldwide provision for income taxes. In the ordinary course of business, there are many transactions and calculations where the ultimate tax determination is uncertain. We are currently subject to tax audits and investigations in several jurisdictions, and may be subject to other audits and investigations in the future. The final determination of any tax audits or related litigation could be materially different from our income tax provisions and accruals.
Additionally, changes in the effective tax rate as a result of a change in the mix of earnings in countries with differing statutory tax rates, changes in our overall profitability, changes in the valuation of deferred tax assets and liabilities, the results of audits and the examination of previously filed tax returns by taxing authorities, and continuing assessments of our tax exposures could impact our tax liabilities and affect our income tax expense, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We may become taxable in a jurisdiction other than the U.K. and this may increase the aggregate tax burden on us.
Based on our current management structure and current tax laws of the U.S., the U.K., and the Netherlands, as well as applicable income tax treaties, and current interpretations thereof, the U.K. and the Netherlands competent authorities have determined that we are tax resident solely in the U.K. for the purposes of the Netherlands-U.K. tax treaty. We have received a binding ruling from the competent authorities in the U.K. and in the Netherlands confirming this treatment. We will therefore be tax resident solely in the U.K. so long as the facts and circumstances set forth in the relevant application letters sent to those authorities remain accurate. Even though we received a binding ruling, the applicable tax laws or interpretations thereof may change, or the assumptions on which such rulings were based may differ from the facts. As a consequence, we may become a tax resident of a jurisdiction other than the U.K. As a consequence, our overall effective income tax rate and income tax expense could materially increase, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We have a number of clean energy investments which are subject to various risks and uncertainties.
We have invested in clean energy operations capable of producing refined coal that we believe qualify for tax credits under Section 45 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). Our ability to claim tax credits under Section 45 of the Code depends upon the operations in which we have invested satisfying certain ongoing conditions set forth in Section 45 of the Code. These include, among others, the emissions reduction, “qualifying technology”, and “placed-in-service” requirements of Section 45 of the Code, as well as the requirement that at least one of the operations’ owners qualifies as a “producer” of refined coal. While we have received some degree of confirmation from the IRS relating to our ability to claim these tax credits, the IRS could ultimately determine that the operations have not satisfied, or have not continued to satisfy, the conditions set forth in Section 45 of the Code. The ability to claim tax credits under these provisions is set to expire in 2021 and may not be renewed.
In addition, Congress could modify or repeal Section 45 of the Code and remove the tax credits retroactively. Further, Section 45 of the Code contains phase out provisions based upon the market price of coal, such that, if the price of coal rises to specified levels, we could lose some or all of the tax credits we expect to receive from these investments. Finally, when the price

36



of natural gas or oil declines relative to that of coal, some utilities may choose to burn natural gas or oil instead of coal. Market demand for coal may also decline as a result of an economic slowdown and a corresponding decline in the use of electricity. If utilities burn less coal, eliminate coal in the production of electricity or are otherwise unable to operate for an extended period of time, the availability of the tax credits would also be reduced. During the past few years, as a result of a decline in current and expected future production levels at certain of our clean energy facilities, the Company impaired its investment balance and other assets and in 2018 we terminated certain of our clean energy investments. Additional impairments or terminations could occur in the future.
The occurrence of any of the above risks could limit the value of our investment, result in increased costs, materially increase our tax burden or adversely affect our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Currency fluctuations and changes in exchange rates could adversely affect our business, financial condition, results of operations, cash flows, and/or ordinary share price.
Although we report our financial results in U.S. Dollars, a significant portion of our revenues, indebtedness and other liabilities and our costs are denominated in non-U.S. currencies, including among others the Euro, Swedish Krona, Indian Rupee, Japanese Yen, Australian Dollar, Canadian Dollar, British Pound Sterling and Brazilian Real. Our results of operations and, in some cases, cash flows, have in the past been and may in the future be adversely affected by certain movements in currency exchange rates. Defaults or restructurings in other countries could have a similar adverse impact. From time to time, we may implement currency hedges intended to reduce our exposure to changes in foreign currency exchange rates. However, our hedging strategies may not be successful, and any of our unhedged foreign exchange exposures will continue to be subject to market fluctuations. The occurrence of any of the above risks could cause a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price
We have significant indebtedness, which could lead to adverse consequences or adversely affect our financial position and prevent us from fulfilling our obligations under such indebtedness, and any refinancing of this debt could be at significantly higher interest rates.
Our level of indebtedness could have important consequences, including but not limited to:
increasing our vulnerability to general adverse economic and industry conditions;
requiring us to dedicate a substantial portion of our cash flow from operations to make debt service payments, thereby reducing the availability of cash flow to fund working capital, capital expenditures, acquisitions and investments and other general corporate purposes;
limiting our flexibility in planning for, or reacting to, challenges and opportunities, and changes in our businesses and the markets in which we operate;
limiting our ability to obtain additional financing to fund our working capital, capital expenditures, acquisitions and debt service requirements and other financing needs;
increasing our vulnerability to increases in interest rates in general because a substantial portion of our indebtedness bears interest at floating rates; and
placing us at a competitive disadvantage to our competitors that have less debt.
Our ability to service our indebtedness will depend on our future operating performance and financial results, which will be subject, in part, to factors beyond our control, including interest rates and general economic, financial and business conditions. If we do not have sufficient cash flow to service our indebtedness, we may need to refinance all or part of our existing indebtedness, borrow more money or sell securities or assets, some or all of which may not be available to us at acceptable terms or at all. In addition, we may need to incur additional indebtedness in the future in the ordinary course of business. Although the terms of our credit agreements and our bond indentures allow us to incur additional debt, this is subject to certain limitations which may preclude us from incurring the amount of indebtedness we otherwise desire.
Although Mylan expects to maintain an investment grade credit rating, a downgrade in the credit rating of Mylan or any indebtedness of Mylan or its subsidiaries could increase the cost of further borrowings or refinancings of such indebtedness, limit access to sources of financing in the future or lead to other adverse consequences.
If we incur additional debt, the risks described above could intensify. If global credit markets contract, future debt financing may not be available to us when required or may not be available on acceptable terms or at all, and as a result we may be unable

37



to grow our business, take advantage of business opportunities, respond to competitive pressures or satisfy our obligations under our indebtedness. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
From time to time, we issue variable rate debt based on the London Interbank Offered Rate (“LIBOR”) or undertake interest rate swaps that contain a variable element based on LIBOR. The Financial Conduct Authority in the U.K. has announced that it will phase out LIBOR as a benchmark by the end of 2021. As of December 31, 2019, less than 10% of our outstanding debt is linked to LIBOR. However, if LIBOR ceases to exist, we may need to renegotiate or amend certain of our agreements and we may not be able to do so on terms that are favorable to us. As a result, our interest expense could increase. In addition, the overall financial market may be disrupted and there could be significant increases in benchmark rates or borrowing costs to borrowers as a result of the phase-out or replacement of LIBOR. Disruption in the financial market, significant increases in benchmark rates or borrowing costs or our inability to renegotiate agreements on favorable terms could have a material adverse effect on our business, financing activities, financial condition and operations.
Our credit facilities, senior unsecured notes, commercial paper program, other outstanding indebtedness and any additional indebtedness we incur in the future impose, or may impose, significant operating and financial restrictions on us. These restrictions limit our ability to, among other things, incur additional indebtedness, make investments, pay certain dividends, prepay other indebtedness, sell assets, incur certain liens, enter into agreements with our affiliates or restricting our subsidiaries’ ability to pay dividends, merge or consolidate. In addition, our credit facilities require us to maintain specified financial ratios. A breach of any of these covenants or our inability to maintain the required financial ratios could result in a default under the related indebtedness. If a default occurs, the relevant lenders could elect to declare our indebtedness, together with accrued interest and other fees, to be immediately due and payable. These factors could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Any future changes in estimates, judgments and assumptions used or necessary revisions to prior estimates, judgments or assumptions or changes in accounting standards could lead to a restatement or revision to previously issued financial statements.
The consolidated and condensed consolidated financial statements included in the periodic reports we file with the SEC are prepared in accordance with U.S. GAAP. The preparation of financial statements in accordance with U.S. GAAP involves making estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues, expenses and income. Estimates, judgments and assumptions are inherently subject to change in the future and any necessary revisions to prior estimates, judgments or assumptions could lead to a restatement. Furthermore, although we have recorded reserves for litigation related contingencies based on estimates of probable future costs, such litigation related contingencies could result in substantial further costs. Also, any new or revised accounting standards may require adjustments to previously issued financial statements. Any such changes could result in corresponding changes to the amounts of liabilities, revenues, expenses and income and could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.
We must maintain adequate internal controls and be able to provide an assertion as to the effectiveness of such controls on an annual basis.
Effective internal controls are necessary for us to provide reasonable assurance with respect to our financial reports. We spend a substantial amount of management and other employee time and resources to comply with laws, regulations and standards relating to corporate governance and public disclosure. In the U.S., such regulations include the Sarbanes-Oxley Act of 2002, SEC regulations and the NASDAQ listing standards. In particular, Section 404 of the Sarbanes-Oxley Act of 2002 requires management’s annual review and evaluation of our internal control over financial reporting and attestation as to the effectiveness of these controls by our independent registered public accounting firm. If we fail to maintain the adequacy of our internal controls, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting. Additionally, internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. Therefore, even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. In addition, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that the control may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, this could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or ordinary share price.

38



ITEM 1B.
Unresolved Staff Comments
None.
ITEM 2.
Properties
For information regarding properties, refer to Item 1 “Business” in Part I of this Annual Report on Form 10-K.
ITEM 3.
Legal Proceedings
For information regarding legal proceedings, refer to Note 20 Litigation included in Item 8 in Part II of this Annual Report on Form 10-K.

39



PART II
ITEM 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our ordinary shares are traded on the NASDAQ Stock Market under the symbol “MYL”.
As of February 18, 2020, there were approximately 101,250 holders of Mylan N.V. ordinary shares, including those held in street or nominee name.
The Company did not pay dividends in 2019 or 2018 and does not intend to pay dividends on its ordinary shares in the near future.
UNREGISTERED SALES OF DEBT SECURITIES
In the past three years, we have issued unregistered securities in connection with the following transactions:
In May 2018, Mylan Inc. issued €500 million aggregate principal amount of senior unsecured debt securities, comprised of 2.125% Euro Senior Notes due 2025. These notes were issued in a private offering exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), to persons outside of the U.S. pursuant to Regulation S under the Securities Act.
In April 2018, Mylan Inc. issued $1.5 billion aggregate principal amount of senior unsecured debt securities, comprised of 4.550% Senior Notes due 2028 and 5.200% Senior Notes due 2048. These notes were issued in a private offering exempt from the registration requirements of the Securities Act, to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to persons outside of the U.S. pursuant to Regulation S under the Securities Act. In November 2018, Mylan N.V. and Mylan Inc. filed a registration statement with the SEC with respect to an offer to exchange these notes for registered notes with the same aggregate principal amount and terms substantially identical in all material respects, which was declared effective on December 11, 2018. The exchange offer expired on January 9, 2019 and settled on January 10, 2019. 100% of each of the 4.550% Senior Notes due 2028 and the 5.200% Senior Notes due 2048 were exchanged. 

40



In May 2017, Mylan N.V. issued €500 million aggregate principal amount of senior unsecured debt securities, comprised of floating rate Senior Notes due 2020. These notes were issued in a private offering exempt from the registration requirements of the Securities Act, to persons outside of the U.S. pursuant to Regulation S under the Securities Act.
STOCK PERFORMANCE GRAPH
Set forth below is a performance graph comparing the cumulative total return (assuming reinvestment of dividends), in U.S. Dollars, for the calendar years ended December 31, 2015, 2016, 2017, 2018 and 2019 of $100 invested on December 31, 2014 in the Company’s ordinary shares, the Standard & Poor’s 500 Index and the Dow Jones U.S. Pharmaceuticals Index.
https://cdn.kscope.io/8b2d78e7e85113497bfbfd6985aa7ca4-stockgraph.jpg
 
December 31,
2014
 
December 31,
2015
 
December 31,
2016
 
December 31,
2017
 
December 31,
2018
 
December 31,
2019
Mylan N.V. (1)
100.00

 
95.92

 
67.68

 
75.06

 
48.61

 
35.66

S&P 500
100.00

 
101.38

 
113.51

 
138.29

 
132.23

 
173.86

Dow Jones U.S. Pharmaceuticals
100.00

 
106.21

 
103.90

 
116.41

 
126.16

 
145.72

____________
(1) 
Mylan Inc. prior to February 27, 2015.

41